Midweek Update

Midweek Update

Simplicity is a virtue.

“Simplicity is not about doing less; it’s about focusing on what matters most. The future of performance management is about creating value with clarity & ease.”

From Washington, DC,

  • BioPharma Dive reports,
    • “A bipartisan House bill proposed Tuesday would require government screening of U.S. investments in Chinese biotechnology in the wake of two pharmaceutical deals potentially worth more than $10 billion each.
    • “Reps. John Moolenaar, R-Mich., chairman of the Select Committee on China, and Debbie Dingell, D-Mich., are sponsoring the bill, dubbed the Biotech Investment National Security Act. It would amend the COINS legislation passed last year to restrict investment in certain sensitive technologies, adding biotechnology to the list.
    • “Under the new bill, licensing deals, joint ventures and equity investments in China could be subject to both Treasury and Defense Department reviews. Moolenaar and Dingell focused on licensing deals involving technology and intellectual property and excluded agricultural biotechnology, industrial fermentation and basic academic research.”
  • Federal News Network relates
    • “Close to 8,000 career federal employees will be moved into a new employment category with limited job protections, after the Trump administration took the final step to make Schedule Policy/Career a reality.
    • ‘An executive order President Donald Trump signed Wednesday afternoon formalizes the long-expected federal employment classification and eliminates civil service protections for thousands of senior-level positions across government. The move is meant to boost workforce accountability, but has also drawn sharp criticism from federal unions, employee organizations and other stakeholders.
    • “Trump administration officials said the creation of Schedule Policy/Career aims to improve employee accountability and ensure the federal workforce is carrying out the president’s policy agenda. Officials also said it’s currently too difficult to remove federal employees for poor performance.
    • “It’s also about a restoration, in our mind, of the democratic process,” Office of Personnel Management Director Scott Kupor told reporters during a press call Wednesday. “What Schedule Policy/Career does is really nothing new. This is exactly the way the system worked for a very long time … In order to affect the policy priorities of the administration, we need to have people willing to and capable of carrying out those directives.” * * *
    • “The targeted 8,000 career federal positions for the new classification is far lower than OPM’s initial estimate that Schedule Policy/Career would cover about 50,000 positions. Some earlier estimates had also suggested as many as 200,000 positions could be converted.”
  • Govexec tells us,
    • “With one protest withdrawn and a second one denied, the Office of Personnel Management is now free to move forward with its plan to award a 10-year contract to modernize the government’s human resource systems.
    • “OPM released the final solicitation in October for the Federal HR 2.0 contract to modernize systems that cover 2 million employees across the government. The agency wants a single integrated platform that will be the infrastructure for a more data-driven federal HR ecosystem, according to solicitation documents.
    • “Bidders had to submit proposals by Oct. 31 and OPM followed a two-step process for evaluation. After step one, IBM Corp. and then Economic Systems Inc. filed their protests.
    • “IBM filed its protest on Feb. 25 but withdrew without explanation on April 3. Meanwhile, Economic Systems filed a protest on March 2. On Monday, the Government Accountability Office posted on its public docket that it had denied Economic Systems protest.
    • “OPM could not make an award while the protests were active, but it could continue to evaluate proposals. Now it can pick a winner with the protests out of the way.
    • ‘While no dollar value has been disclosed, the undertaking is massive.”
  • Kevin Moss, writing in Federal News Network, encourages federal employees to take a look at joining FEHB and PSHB high deductible plans that allow them to contribute to triple tax deductible health savings accounts.

From the Food and Drug Administration front,

  • U.S. News and World Report reports,
    • “Acting U.S. FDA Commissioner Kyle Diamantas met ⁠with ⁠rare disease groups on Wednesday, according to groups ⁠attending and a government official, as the new chief seeks to repair relations with a sector disappointed ​by his predecessor.
    • “Representatives for rare disease organizations including Friends of Cancer Research and the Foundation for Angelman Syndrome Therapeutics are pushing Diamantas for greater certainty and support ‌for treatments for small patient populations, the ‌groups said.
    • “The acting chief is seeking to steady operations and mend fences following Commissioner Marty Makary’s resignation last month. Makary had clashed with the White ⁠House over issues including ⁠vaping products.
    • “Jeff Allen, CEO of Friends of Cancer Research, in a phone interview with Reuters ​following the meeting, described it as a “breath of fresh air.”
  • MedTech Dive relates,
    • “Edwards Lifesciences said it has secured FDA approval for the first surgical valve replacement designed for patients with tricuspid valve disease.
    • “The approval introduces a surgical option for a long-underserved area of structural heart care, extending Edwards’ Resilia tissue technology to the tricuspid position, a spokesperson told MedTech Dive in an email. 
    • “Called Triformis Resilia, the valve has a flattened sewing ring shape that mirrors the native tricuspid valve’s annulus anatomy.”

From the judicial front,

  • STAT News reports,
    • ‘A fourth major health insurer is suing HaloMD over its use of the No Surprises Act’s arbitration process, arguing that the middleman deceived arbitrators by sending them a “sham letter” and misleading price data. 
    • “Highmark Health, a Pennsylvania-based Blue Cross Blue Shield licensee with over 7 million members, claims in a complaint filed June 1 in U.S. District Court in Western Pennsylvania that HaloMD and one of its clients, a neuromonitoring provider called Bromedicon, submitted more than 450 ineligible disputes with the company and won more than $3.9 million. Like the three Blue Cross plans before it, Highmark wants those awards tossed and its money returned.” * * *
    • “Other insurers have so far gotten chilly receptions to their suits. Judges in California and Texas have dismissed similar lawsuits against HaloMD and its provider clients, finding their allegations — that the company deliberately submitted ineligible disputes and won huge payouts anyway — didn’t warrant the court’s review. The rulings don’t bode well for Highmark or outstanding cases in Georgia and Ohio.”

From the public health and medical / Rx research front,

  • The Wall Street Journal reports,
    • “Eating a diet high in ultraprocessed foods is associated with an increased risk of dementia, according to new research, adding to the growing list of health problems linked to foods such as packaged cookies, hot dogs and chips.
    • “In a study published Wednesday in the American Journal of Public Health, the group of people who reported eating the highest amount of ultraprocessed foods had a 58% higher risk of later developing dementia and a 46% increased risk of developing cognitive impairment than those who said they ate the least.” * * *
    • “Nutrition researchers generally define ultraprocessed foods as items containing ingredients that wouldn’t generally be found in a home kitchen, such as emulsifiers—used to improve the texture of food—and high-fructose corn syrup. 
    • “The new study found that diets high in minimally processed foods, such as fresh fruits, vegetables, whole grains, fish and unprocessed meats, were linked to a decreased risk of dementia and cognitive impairment. People who ate the most minimally processed foods had a 41% lower risk of dementia compared with those who ate the least.”
  • and
    • “New research suggests anesthesia may be closer to being in a coma than previously thought, not just a deep sleep.
    • “Researchers compared brain-wave data from anesthetized patients with those awake, asleep or in a coma.
    • “Understanding these brain patterns could help redesign anesthesia to resemble natural sleep, reducing postoperative issues, experts say.”
  • MedPage Today relates,
    • “Deaths of despair — fatalities from drugs, alcohol, and suicide — declined by 16% in 2024, according to a report from Trust for America’s Health.
  • and
    • “Weight loss is known to reduce the need for joint replacement surgery in overweight or obese people with knee osteoarthritis (OA), and glucagon-like peptide-1 (GLP-1) receptor agonists are an established way to lose weight.
    • “This study of health records demonstrated that use of GLP-1 drugs was associated with reduced arthroplasty rates, with longer exposure leading to correspondingly lower rates.
    • “Reasons for initiating GLP-1 drug therapy were not known, however, and weight loss was not tracked over time, so the mechanisms underlying the observed associations remain unknown.”
  • Gastroenterology Advisor tells us,
    • “A baseline colonoscopy among individuals aged 40 to 49 years is associated with a significantly reduced risk for colorectal cancer (CRC), especially for men aged 45 to 49 years, according to study results published in the American Journal of Gastroenterology.” * * *
    • “These findings provide large-scale observational evidence that the risk-reducing association of an early baseline evaluation becomes increasingly apparent over several years of follow-up,” the study authors stated.”
  • Health Day notes,
    • “Scientists may be one step closer to staging Alzheimer’s disease with a simple blood test.
    • “The test could offer a cheaper, less invasive alternative to brain scans and spinal taps now used to diagnose and determine the extent of disease.
    • “Researchers developed a model that uses just two forms of tau protein in the blood to track Alzheimer’s progression. They tried it on more than 1,000 patients, including people who were cognitively unimpaired, patients with mild cognitive impairment, patients with Alzheimer’s dementia and people with other neurodegenerative diseases.
    • “The result: Staging from the blood model closely matched the accuracy of PET brain scans.”
  • and
    • “Population-based screening for early-stage type 1 diabetes identifies most children who progress to clinical type 1 diabetes, with additional cases detected with repeat screening, according to a study published online May 21 in the Journal of the American Medical Association.”

From the U.S. healthcare business and artificial intelligence front,

  • Beckers Payer Issues reports,
    • “Cigna will stop covering GLP-1s for weight loss through its own employee health plan July 1, the company confirmed to Becker’s.
    • “We regularly review our health benefits to ensure they remain sustainable, accessible and aligned with the unique needs of our workforce. As availability has increased and new options have emerged, we’ve made the decision to end our plan’s coverage for GLP-1s for weight loss,” a company spokesperson said. “We remain committed to supporting our employees’ health through a range of weight-management programs and resources.”
    • “The change will not apply to those using GLP-1s for diabetes, the spokesperson said. It also will not apply to Cigna plans beyond its own, a spokesperson confirmed to Reuters, which first reported the development June 2. GLP-1 users for weight loss have until June 30 to obtain refills. 
    • ‘An internal document reviewed by Reuters said employees can pay for these drugs with cash directly through manufacturer websites or TrumpRx. However, that spending would not count toward deductibles. Cigna will continue to cover generic weight-loss drugs that predate GLP-1s, such as phentermine, diethylpropion, benzphetamine and phendimetrazine, according to Reuters.
    • “Cigna joins a wave of healthcare employers cutting back GLP-1 access for their workers as cost pressures mount.”
  • The Wall Street Journal provides “Five Takeaways From the WSJ’s Autism Billing-Abuse Investigation — Insurers’ fraud warnings, a nearly $1 million surprise therapy bill and the back story of a visit to the Brooklyn-based provider the Perfect Child.”
  • MedTech Dive relates,
    • “Medtronic ended its fiscal year on a high note, growing revenue by nearly double digits in its fiscal fourth quarter.
    • “The medtech company brought in $9.8 billion of revenue in the quarter, representing year-over-year growth of nearly 10%. The performance was better than expected, J.P. Morgan analyst Robbie Marcus said in a note to investors.
    • CEO Geoff Martha said Medtronic delivered its strongest annual top-line growth in 10 years.
    • “Through a dynamic macro environment, we have executed, and we’ve executed with discipline to deliver an excellent fiscal ’26 that will continue into fiscal ’27,” Martha told investors Wednesday morning.
    • “The performance was driven by solid sales for its cardiovascular unit and strong growth for businesses within the segment.”
  • The Wall Street Journal inform us,
    • “Eli Lilly LLY signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
    • “Ascidian, a Boston-based biotechnology company, said Wednesday it granted Eli Lilly exclusive, target-specific rights to its RNA-exon-editing technology for undisclosed kidney-disease targets.
    • “The RNA-exon editors are capable of altering parts of genetic code to repair genetic instructions that cause disease.
    • “Ascidian said it will lead discovery and certain preclinical activities, while Eli Lilly will be responsible for other preclinical work, clinical development, manufacturing and commercialization.
    • “Ascidian is eligible to receive up to $1.9 billion, including an upfront payment, development and commercial milestone payments, and tiered royalties on commercial sales worldwide, it said.”
  • Fierce Healthcare tells us,
    • “Mayo Clinic plans to develop and deploy a frontier AI model specifically designed for healthcare in collaboration with Microsoft. 
    • “The strategic collaboration combines Mayo Clinic’s global healthcare expertise, de-identified clinical health data and longitudinal insights with Microsoft’s advanced AI, cloud engineering and tech capabilities, the companies announced Tuesday.
    • “The two organizations say they are developing a frontier AI model “capable of supporting the broadest scope of clinical reasoning and healthcare use cases,” according to a press release.
    • “The frontier AI model is designed to synthesize diverse clinical data to support earlier diagnoses, more personalized treatment decisions and better patient outcomes. The AI collaboration will make Mayo Clinic’s medical expertise and integrated model of care available to more people when and where they need it, the two organizations said.”
  • Beckers Hospital Review adds,
    • “Washington, D.C.-based Children’s National Hospital has introduced a pediatric AI innovation hub to translate the technology from concept to bedside use.
    • “The partnership with Blacksburg-based Virginia Tech will bring together pediatric clinicians, biomedical researchers and AI specialists to create advancements for what has been an underserved community thus far in the technology’s evolution.
    • “Children have historically been underrepresented in AI research despite having fundamentally different physiology, disease patterns and developmental needs,” said Marius George Linguraru, director of AI research at Children’s National, in a June 2 news release. “We have an opportunity to build pediatric AI the right way from the beginning by developing and validating these technologies specifically for children and within pediatric clinical settings.”
  • Fierce Pharma points out,
    • “Pharma solutions firm Cencora and Gilead Sciences have expanded their longstanding partnership, cutting a deal in which the distribution giant will support access to Gilead’s CAR-T cancer therapies Yescarta and Tecartus.
    • “The collaboration is designed to facilitate more efficient access to the blood cancer therapies, which were developed by Gilead’s CAR-T subsidiary Kite Pharma. 
    • “Under the agreement, Cencora will leverage its substantial distribution infrastructure to bolster cell therapy availability at an “increasing number” of authorized U.S. treatment centers, including health systems and community oncology practices, according to a June 2 release.” 
  • HR Dive lets us know,
    • “Workers over age 55 make up almost a quarter of the workforce (23.2%), according to a report from MyPerfectResume. Moreover, according to researchers, the growth of the older workforce outpaces the general workforce. Likewise, the share of workers over age 65 increased by more than 40%, according to the report.”

Monday report

Simplicity is a virtue.

From Washington, DC,

  • Roll Call reports on this week’s anticipated activities on Capitol Hill.
    • “After a weeklong recess, Senate Republicans return Monday with their focus set on ways to move their budget reconciliation package, which hit several hurdles before the Memorial Day break. 
    • “The House, which has been on standby while Senate leadership works out how much of the White House wishlist they can salvage, is returning later this week, with its first vote scheduled for Wednesday.”
  • The Wall Street Journal adds,
    • “The Trump administration signaled a retreat Monday on its nearly $1.8 billion “anti-weaponization” fund, which met powerful pushback from members of Congress and threatened to derail the president’s efforts to pass immigration-enforcement funding.”
  • Yesterday, the FEHBlog described OPM’s family member documentation guidance as an interim final rule because OPM had not issued a proposed rule. However, it turns out that OPM decided that public comment was unnecessary so it declared the guidance to be a final rule. The final rule will be published in the Federal Register tomorrow which means that the final rule’s effective date is July 2, 2026.
  • Federal News Network also relates,
    • “Agencies will soon be able to pay as much as $400,000 a year to certain employees with skillsets in the national security sector. President Donald Trump told the Office of Personnel Management on Friday to establish new regulations to pay experts in specific fields related to supply chain resilience, secure access to critical minerals and advanced technologies and advance priority investment programs essential to national defense and economic security. The memo said this increase in the top line pay for these positions is necessary to advance the rapid recruitment of the exceptionally skilled investment, engineering, financial and legal professionals needed to expand the nation’s capacity.”
  • Govexec notes,
    • “For the second straight month, each portfolio offered by the federal government’s 401(k)-style retirement savings program finished May in the black.”
  • The final rule making changes to the No Surprises Act’s independent dispute resolution process is scheduled to be published in the Federal Register on June 4, 2026.
  • Radiology Business tells us,
    • “Radiologists, anesthesiologists and emergency medicine physicians are jointly praising recently announced changes to the No Surprises Act while also pushing for further reform. 
    • “Medical societies representing all three specialties shared their official response to the independent dispute resolution, or IDR, final rule on Friday. Released by the Centers or Medicare & Medicaid Services May 28, the rule finalizes many updates to the NSA first proposed back in 2023.
    • “The American College of Radiology, American Society of Anesthesiologists and the American College of Emergency Physicians commended the rule, calling it a “thoughtful and collaborative approach.” They see the changes as an “important step forward,” one that will hopefully create a “more functional, transparent dispute resolution system.” 
  • These comments confirm the FEHBlog’s opinion that a follow up rule or perhaps a statutory change is needed to level the IDR process playing field which currently favors this healthcare providers.
  • The American Hospital Association News informs us,
    • “President Trump signed an executive order May 29 that directs the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices to review a scientific assessment by the Department of Health and Human Services on childhood vaccine recommendations from other developed nations. The order recommends the CDC and ACIP take any appropriate steps to update the U.S. childhood and adolescent vaccine schedule to align it with those from other nations. The administration also recommended that all immunizations on the schedule should continue to be covered without cost sharing by private insurers and covered by Medicaid, the Children’s Health Insurance Program and the Vaccines for Children Program.”
  • and
    • “The Centers for Medicare & Medicaid Services June 1 issued an interim final rule with comment period implementing the statutory requirement that certain adult Medicaid enrollees meet community engagement (work) requirements. Under the rule, certain adults must complete 80 hours per month of “qualifying activities,” such as employment, education, community service or participation in a work program, or meet equivalent income thresholds.
    • “CMS said that states must generally implement the requirement no later than Jan. 1, 2027. The rule maintains exemptions for certain populations, including individuals who are pregnant or postpartum, disabled or medically frail, or caregivers, and allows states to offer exemptions for short-term hardships. See the CMS fact sheet for more details.
    • “Provisions in the rule are effective on July 31, 2026, and comments must be submitted by that date.”

From the Food and Drug Administration front,

  • MedPage Today reports,
    • “The FDA approved the oral antiviral agent ensitrelvir (Xocova) to help prevent COVID-19 in people ages 12 years or older who were exposed to the SARS-CoV-2 virus, drugmaker Shionogi announcedopens in a new tab or window.
    • “Ensitrelvir is a SARS-CoV-2 main protease inhibitor also approved in Japan as COVID-19 postexposure prophylaxis (PEP) and as a treatment for mild to moderate COVID. The drug is not approved to treat COVID-19 in the U.S.
    • “The FDA’s decision was based on the phase III SCORPIO-PEP trial, which showed the risk of getting sick from a household contact with COVID-19 dropped by more than half among those who took ensitrelvir compared with placebo.”
  • Contemporary OB/GYN relates,
    • “Wockhardt has announced that the FDA has approved cefepime and zidebactam (ZAYNICH; Wockhardt), a novel intravenous antibiotic designed to treat adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens. The approval offers a new therapeutic option for patients facing aggressive, drug-resistant infections. Prior to this approval, the drug received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.
    • “In the United States, cUTIs are responsible for over 600,000 hospitalizations annually. A growing proportion of these infections are driven by antimicrobial-resistant bacteria, which represent a leading cause of bacteremia and carry significant morbidity and mortality risks. These multidrug-resistant infections place a heavy burden on the healthcare system, as affected patients typically require more intensive, prolonged care and experience higher rates of life-threatening complications.
    • “The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of ZAYNICH is a monumental step forward in validating a new option for these underserved populations,” said Dr. Dennis Deruelle, Chief Medical Officer at Wockhardt.”

From the judicial front,

  • CMS posted a notice of a court decision that will appear in tomorrow’s Federal Register,
    • SUMMARY: This is to inform the public that, on October 22, 2025, the United States District Court for the Southern District of Mississippi issued an order in Tennessee v. Kennedy, No. 1:24-cv-161-LG-BWR (S.D. Miss. Oct. 22, 2025), vacating portions of the final rule titled “Nondiscrimination in Health Programs and Activities,” published May 6, 2024 (89 FR 37522).
    • Specifically, the court vacated certain provisions of the regulation to the extent they expand Title IX’s definition of sex discrimination to include gender-identity discrimination. Pursuant to the court’s order, the vacated provisions are legally void. The other provisions of the Section 1557 Rule remain in force.
    • DATES: The Tennessee court issued its vacatur order on October 22, 2025. As long as the specified provisions of the 2024 Section 1557 Rule remain vacated, OCR and CMS cannot and will not enforce the vacated provisions.

From the public health and medical/Rx research front,

  • The Wall Street Journal reports,
    • “An outbreak of a rare strain of Ebola in the Democratic Republic of Congo is already the third largest in history, just weeks after it likely began.
    • “It is spreading rapidly in one of the most volatile and vulnerable regions of the world, worrying U.S. and international health officials.” * * *
    • “What are the chances that Ebola will spread to the U. S.?
    • “The risk is low, according to the Centers for Disease Control and Prevention. U.S. officials have prohibited foreigners who have been to Congo, Uganda or South Sudan in the last three weeks from entering the country. U.S. citizens who have been to those countries are being directed to four U.S. airports and screened there, the CDC said. Those airports are: Washington-Dulles International, Hartsfield-Jackson Atlanta International, George Bush Intercontinental and John F. Kennedy International.
    • “The U.S. has a network of specialized treatment centers around the country to care for patients with dangerous pathogens like Ebola and hantavirus, at hospitals such as the University of Nebraska Medical Center and Emory University Hospital. However, U.S. authorities evacuated an American medical missionary who contracted Ebola in Congo to a hospital in Germany with similar capabilities, and aim to build an Ebola quarantine and treatment facility in Kenya. A Kenyan high court put the U.S. plan on hold.”
  • The American Medical Association lets us know what doctors wish their patient knew about lupus.
    • “Lupus is a complex autoimmune disease with varied symptoms. Early diagnosis and ongoing care can help patients manage flares and protect long-term health.”
  • MedPage Today relates,
    • “The cigarette smoking rate among U.S. adults dropped to another all-time low last year, with one in 11 adults saying they were current smokers, according to new government survey data.
    • “Cigarette smoking is a risk factor for lung cancer, heart disease, and stroke, and it’s long been considered the leading cause of preventable deathopens in a new tab or window.
    • “The preliminary findingsopens in a new tab or window from the CDC were based on survey responses from more than 24,200 adults. In the survey, CDC officials defined current cigarette smoking as smoking at least 100 cigarettes in a lifetime and now smoking every day or some days.” * * *
    • “In 2024, the percentage of current adult smokers fell below 10% for the first time. Last year, it was 9%, according to the new survey.
    • “The use of electronic cigarettes has been inching up among adults, but has held about steady in 2025, at about 7%.”
  • Per a National Institutes of Health news release,
    • “The National Institutes of Health (NIH) today announced that its Investigational New Drug (IND) application for mitragynine, the primary psychoactive compound found in Mitragyna speciosa (kratom), has taken effect with the U.S. Food and Drug Administration (FDA). The IND paves the way for an NIH-led phase I clinical trial to evaluate mitragynine as a potential treatment for opioid use disorder.
    • “Researchers at NIH and the University of Florida developed the purified formulation of mitragynine to be used in the trial, as well as the preclinical work that led to the submission of the IND application.
    • “This IND is a major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder, which has contributed to historically high overdose mortality rates,” said Nora Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA).”
  • The American Journal of Managed Care tells us,
    • “People living with alopecia areata (AA) may not face a heightened risk of skin cancer despite reduced scalp hair coverage, according to a new systematic review and meta-analysis that found a significantly lower incidence of melanoma among this patient population.
    • “The analysis, published in Frontiers in Oncology, evaluated data from more than 860,000 patients across 8 retrospective studies conducted in the US, Sweden, Denmark, Taiwan, and the Republic of Korea. Researchers reported that AA was associated with a statistically significant reduction in melanoma incidence, whereas rates of basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and overall skin cancer also trended lower but did not consistently reach statistical significance.
    • “The findings arrive as clinicians increasingly prescribe Janus kinase (JAK) inhibitors for moderate to severe AA, raising questions about long-term malignancy risks and the need for baseline disease-specific cancer data.”
  • Fierce Pharma informs us,
    • “AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3 readout from its Emerald trial program assessing the immunotherapy duo in a locoregional setting. 
    • “The phase 3 Emerald-3 study, presented June 1 at the Annual Society of Clinical Oncology (ASCO) 2026 annual meeting in Chicago, positions AZ’s Imfinzi/Imjudo regimen as a “compelling therapeutic option” for patients with unresectable embolization-eligible hepatocellular carcinoma (HCC), ASCO expert Vishwanath Sathyanarayanan, M.D., commented in an ASCO press release.” 

From the U.S. healthcare business front,

  • Modern Healthcare reports,
    • “The public and private sector are committed to value-based care as a solution to high healthcare spending.
    • “Decades of value-based care interventions have not reversed perpetually rising health expenditures.
    • “UnitedHealth Group, CVS Health and other companies have made value-based care central to their business plans.
    • “The fragmented healthcare system remains an obstacle to cost containment.”
  • Beckers Hospital Review relates,
    • “Orlando (Fla.) Health recorded an operating income of $47.4 million (1.9% operating margin) in the second quarter of 2026, down from $94.7 million (3.9% margin) during the same period last year, according to its May 26 financial report.”  
  • KFF Health News, writing in Fierce Healthcare, tells us,
    • “Most patients who have taken a GLP-1 received their prescription through a primary care doctor or a specialist, KFF polling data shows. But as the uptake of telehealth has grown substantially since the start of the covid pandemic, * * * millions of Americans who have used online companies to meet a variety of their medical needs.
    • “Many of the companies have started offering GLP-1 medications for weight loss as demand for these drugs has exploded. But certain medication errors tied to GLP-1s have exploded too, according to a KFF Health News review of Food and Drug Administration data, and physicians and telemedicine researchers worry that adverse experiences tied t”o telehealth companies are becoming more common.
    • Bad outcomes aren’t unique to telehealth providers or to the compounded weight loss drugs many of them offer. In fact, product liability lawsuits alleging patient injuries have been filed overwhelmingly against pharmaceutical giants Eli Lilly and Novo Nordisk, which manufacture name-brand weight loss drugs, court data shows. The drugmakers have defended their products.
    • “However, some critics are also concerned that getting a weight loss prescription online is usually much easier than getting one through an in-person appointment. Not only do many telehealth companies write quick prescriptions for GLP-1s, but they often sell the medications, too, allowing patients to bypass in-person pharmacy visits. This one-stop shopping isn’t necessarily a good thing, according to critics who say some telehealth providers are writing prescriptions for people who should not be taking GLP-1s and then providing little or no follow-up care.
    • “It gives a black eye to telemedicine,” said Elizabeth Krupinski, an experimental psychologist at Emory University who has conducted research on the effectiveness of telehealth.”
  • Fierce Healthcare informs us,
    • “Weight loss company Noom is offering an at-home biomarker testing kit for its U.S. members, expanding its platform into diagnostics and metabolic health monitoring.
    • “It marks an expansion of the company’s proactive health program, which rolled out in December, offering microdose GLP-1 medications combined with at-home biomarker testing and insights.
    • “The at-home blood collection and lab testing service enables members to establish baseline labs and track improvements in markers such as, HbA1C, ApoB, triglycerides and hs-CRP over time, according to the company. Testing gives users with insights into biological outcomes, such as blood sugar regulation, lipid profiles and inflammation markers. By using the kit, members can skip a lab visit and receive results within about a week, paired directly with access to medication and behavior change programs, according to executives.
    • “Noom says it now provides a platform where members can test, act and track A1C improvement in a single, integrated experience.
    • “The biomarker test kits cost $125.”
  • Fierce Pharma points out,
    • “In its seventh week on the market, which ended May 22, Eli Lilly’s obesity pill Foundayo continued to track below the pace of Novo Nordisk’s rival Wegovy pill at the same point in its launch.
    • “At the same time, analysts at Jefferies and Citi again flagged caveats that could be skewing the numbers, with the Jefferies team espousing confidence that Lilly’s oral GLP-1 can still meet consensus sales projections for both the second quarter and 2026 as a whole. 
    • “Breaking down the numbers, the Jefferies team put seventh-week total Foundayo prescriptions lower versus the previous week at roughly 11,700, with the clarification that the data’s source, IQVIA, had to use a “best-estimate” tally for the latest week’s prescription trends. 
    • “That trend remains “numerically lower” than the course charted by Novo’s Wegovy pill, which racked up an impressive 67,000 prescriptions in its seventh week, although Foundayo’s performance still tracks ahead of Novo’s injectable Wegovy and Lilly’s first obesity incretin med Zepbound at the same point in their respective rollouts, the analyst team said.” 

Weekend Update

Simplicity is a virtue

From Washington, DC,

  • Per a House notice,
    • “On Thursday, June 4, 2026, at 10:00 a.m. ET, the Subcommittee on Government Operations will hold a hearing titled “Hearing with the Commissioners of the Postal Regulatory Commission.” The hearing will convene in room 2154 of the Rayburn House Office Building.”
  • Late Friday afternoon, the U.S. Office of Personnel Management placed on the Federal Register’s public inspection list an interim final rule on collection of family member status documentation proving eligibility for FEHB or PSHB coverage as a family member.
    • “The FEHB Protection Act of 2025 (FPA) requires OPM to issue regulations and implement a process to verify: The veracity of any qualifying life event (QLE) through which a health benefits plan enrollee seeks to add a member of family to their enrollment and that when an enrollee adds a family member to the health benefits plan, including during any open season, the individual is a qualified member of family. This final rule also clarifies responsibilities for initial family member eligibility determinations for the Postal Service Health Benefits (PSHB) Program.”

From the American Society of Clincal Oncology’s annual meeting,

  • The Wall Street Journal reports,
    • “Brain tumors are one of the most devastating consequences of cancer’s spread—hard to treat and highly deadly. Scientists have found that using a radioactive implant precisely where a tumor was removed in the brain can help patients get their cancer treated more quickly and in many cases, live longer.
    • “A new study showed that GammaTile, a radioactive wafer the size of a postage stamp, nearly doubled survival rates and nearly eliminated tumor regrowth in people who had it placed in the spot where brain tumors were surgically removed.
    • “Between 100,000 and 200,000 Americans a year are diagnosed with cancer so advanced it has spread to the brain. Typically, patients get those tumors surgically removed and follow up with radiation therapy from a device outside of their body, rather than from within it.
    • “The tiles are already cleared by the Food and Drug Administration. Until this study, which will be presented at the American Society of Clinical Oncology annual meeting this weekend, no large randomized trial had shown that they worked better than the traditional approach for these types of brain tumors.
    • In the new study, involving 230 people, nearly two-thirds of those given the tiles were alive two years later, compared with around a third of those who got standard radiation after surgery. Tumors grew back at the surgical site in just 1% of patients who got the implants, versus 12% of those who got the standard treatment.
    • “That survival difference is pretty astonishing,” said Dr. Molly Blau, a radiation oncologist at Fred Hutch Cancer Center in Seattle who wasn’t involved in the study. Blau said the results could fuel conversations with surgeons at her institution about investing in a GammaTile program.”
  • BioPharma Dive relates,
    • “An experimental drug from Revolution Medicines has proven broadly effective against an aggressive and tough-to-treat pancreatic tumor in a highly anticipated study result that could quickly change medical practice. 
    • “Revolution disclosed in April that the drug, daraxonrasib, nearly doubled survival compared to standard chemotherapy in a Phase 3 trial. At the American Society of Clinical Oncology meeting on Sunday, study investigators provided fuller details experts described as “unprecedented” and “landscape changing.”
    • Revolution’s primary study objective was to test whether daraxonrasib could benefit pancreatic cancer patients whose disease had spread despite a previous treatment and whose tumors were driven by a particular “RAS G12” mutation. But it also evaluated daraxonrasib’s effects on the entire trial population as a secondary outcome, too.
    • “Data presented at ASCO show Revolution’s drug extended survival by a median of 13.2 months among all recipients. By comparison, those who got chemotherapy and had RAS G12 mutations lived a median of 6.6 months. And that figure was comparable — 6.7 months — for all treated with chemo. 
    • “The benefits were similarly stark on measures of disease progression. For people with a RAS G12 mutation, daraxonrasib held tumors in check for a median of 7.3 months. For all drug recipients, that number was 7.2 months. Both numbers doubled the 3.5 month and 3.6 month median survival observed, respectively, among those groups of chemo recipients. 
    • “These results are landscape-changing for metastatic pancreatic cancer patients with a KRAS mutation,” said Rachna Shroff, hematology and oncology chief at the University of Arizona Cancer Center, in a statement provided by ASCO. “We are seeing unprecedented survival and efficacy in second-line treatment with an expected safety profile.”  
  • and
    • “A double-barreled cancer immunotherapy extended the lives of people with lung cancer in a closely watched trial that’s viewed as important for gauging the potential impact of the drug, known as ivonescimab, as well as others like it. 
    • “Presented at the American Society of Clinical Oncology meeting Sunday, the findings come from a study testing ivonescimab in patients newly diagnosed with advanced, non-small cell lung cancer. Though run only in China, the study is a proxy for a global trial that could be worth tens of billions of dollars to the drug’s developers, Akeso and Summit Therapeutics. Like that global study, the China trial is testing an ivonescimab-chemotherapy combination against the kind of immunotherapy-chemo regimen that’s standard care for many new patients. 
    • “Last year, Akeso and Summit revealed that the ivonescimab regimen reduced the risk of disease progression by 40% when compared to chemo and an immunotherapy called Tevimbra. But they hadn’t yet disclosed whether the drug regimen extended lives, the gold standard for a cancer medicine. 
    • “Success in that objective carries implications not only for Akeso and Summit, but many others developing medicines like ivonescimab, which are known as “PD-1/VEGF inhibitors” because of the two proteins they target. These drugs have shown the potential to top widely used immunotherapies like Keytruda, sparking hope that they may become future cornerstones of cancer care. But modest results in some studies have stirred debate about their additive benefits.
    • “Heading into the ASCO presentation, multiple Wall Street analysts pegged a reduction in death risk of anywhere from 20% to 30% as indicative of a meaningful benefit. Ivonescimab hit that mark, with investigators disclosing Sunday that drug recipients lived a median of 28 months after enrollment, versus 24 months for the control group — a 34% relative risk reduction that was statistically significant.” 
  • Fierce Pharma tells us,
    • “With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap.
    • “For patients with high-risk localized or locally advanced prostate cancer, surgical removal of the prostate (radical prostatectomy) is a key standard treatment alongside radiation therapy. But nearly half of patients who move forward with curative-intent surgery ultimately see their cancer return, requiring additional treatment and potentially missing the window in which a cure is possible.  
    • “Additional therapies often intervene only after the cancer has spread, limiting the chance to improve long-term outcomes. This has been the status quo essentially since the prostatectomy was introduced 125 years ago in 1904, J&J’s U.S. president of oncology for solid tumors, Biljana Naumovic, M.D., told Fierce in an interview on the sidelines of the 2026 American Society of Clinical Oncology (ASCO) annual meeting.”
    • “With its phase 3 Proteus study, J&J sought a solution—a way to meet the “one chance for curing this patient,” Mark Wildgust, Ph.D., J&J’s VP of global medical affairs for oncology, said in the joint interview. 
    • “In Proteus, when Erleada was given to patients with high-risk localized or locally advanced disease alongside hormone therapy (androgen deprivation therapy or ADT) for six months before and after surgery, the drug was able to provide significant improvements in “key short- and long-term clinical outcomes,” the company said in a May 31 release. 
    • “Patients who used Erleada and hormone therapy were nine times more likely to have “little to no” cancer remaining at the time of surgery compared with those on hormone therapy alone, with the treatment arm linked to a 8.9% rate of pathologic complete response/minimal residual disease compared to 1% among the hormone therapy-only group, the company said.
    •  “The regimen also reduced the risk of developing metastasis or death by 20% and extended the time before patients required additional therapy to more than six years, J&J reported. That latter figure nearly doubled the three and a half years experienced by those on hormone therapy alone.” 

From the U.S. healthcare business and artificial intelligence front,

  • MedCity News reports,
    • “Garner Health, a digital platform connecting patients with high-performing providers, announced Thursday that it has raised $100 million in Series E funding.
    • “The company serves employers and has a dataset of over 60 billion medical records that helps identify the best quality doctors. When members choose high-performing providers through Garner’s dataset, their employer then covers most or all of their out-of-pocket costs. This incentivizes employees to choose better doctors and lowers costs for employers by avoiding unnecessary procedures.
    • ‘This comes at a time when the “cost crisis” for employers is especially acute, according to Nick Reber, Garner Health CEO.” 
  • BioPharma News relates,
    • “Pfizer is the latest multinational pharmaceutical firm to turn to China for help discovering new medicines, striking late Thursday an expansive alliance with Innovent Biologics potentially worth more than $10 billion.
    • “The deal involves up to 12 cancer drugs, eight of which are early-stage prospects from Innovent, while the remaining four are “Pfizer-proposed” discovery programs. All are newer types of “antibody-drug conjugates” or “multispecific” antibodies — technologies that are becoming more popular in treating cancer.
    • “Innovent will handle discovery work and early research, with Pfizer taking over global development after Phase 1 testing. Pfizer will get worldwide rights, and cover all the costs for four programs. It’ll gain ownership outside of greater China to another four of those drugs, and then will equally split rights and development costs with Innovent on the other four prospects in the deal.
    • “All told, Innovent is receiving $650 million up front and is eligible for another $9.85 billion in downstream payouts should a variety of milestones be met. The Suzhou, China-based company would get royalties on the sales of any approved medicines emerging from the deal, too.” * * *
    • “These deals are causing consternation in biotech circles and sounding alarm bells in Washington D.C., as they’ve threatened the U.S.’ long-held edge and given China growing influence over pharmaceutical development. Yet they’ve continued apace without interference and, of late, have started to broaden in scope, with companies in China and the U.S. forming pacts that cater to their respective advantages, discovering medicines and selling them globally.”
  • Beckers Health IT tells us,
    • “Microsoft has launched a preview version of Copilot Health, an AI-powered platform that allows users to aggregate health records, wearable device data and other personal health information in one place.
    • “The tool is available to U.S. users ages 18 and older who subscribe to Microsoft 365 Personal, Family or Premium plans. Users can access the platform through Copilot’s web interface using a consumer account.
    • “According to a May 29 Microsoft news release, Copilot Health enables users to build personal health profiles, connect Apple Health data and access records from more than 50,000 U.S. provider organizations.
    • “Microsoft said the platform can answer health-related questions, provide personalized insights based on users’ health information and help users identify healthcare providers by specialty, language, insurance coverage and location.
    • “Microsoft said health conversations within Copilot Health are kept separate from other Copilot interactions and are not used to train AI models. Users can manage or remove connected health data sources, and information is encrypted in storage and during transmission.”

Cybersecurity Saturday

From the War with Iran front

  • SC Media reports,
    • The Iran state-sponsored threat group Nimbus Manticore conducted attacks during the U.S.-Israel military campaign Operation Epic Fury targeting the U.S. aviation industry and others for deployment of a new AI-assisted backdoor called “MiniFast,” Check Point Research reported Friday [May 22].
    • The attacks, seen throughout the 2026 Iran war in March, followed previous campaigns throughout February using an older backdoor called MiniJunk. Both waves of attacks utilized career-themed phishing lures for initial access and AppDomain hijacking techniques to execute malicious payloads. * * *
    • Check Point said Nimbus Manticore has shifted tactics in its most recent attacks, seen after the Iran war ceasefire in April, using search engine optimization (SEO) poisoning to impersonate the software Oracle SQL Developer and spread MiniFast.
    • “MiniFast, the successor of MiniJunk, enables extensive control of the victim’s machine through API-based communications with the attacker’s command-and-control (C2) server. As in previous attacks, Nimbus Manticore used career-themed phishing lures to spread MiniFast during Operation Epic Fury, specifically impersonating a U.S. domestic airline.”
  • Cybersecurity Dive adds,
    • “Iranian government-linked hackers sabotaged the computer infrastructure of Los Angeles’s transit system by using access to a virtual machine to delete critical operating-system data, the Israeli cybersecurity firm Gambit Security said in a report published on Tuesday.
    • “The same threat actor also conducted data-wiping attacks on the South Florida Regional Transportation Authority, the connected-vehicle technology firm Agnik and a Saudi Arabian construction company that handles critical infrastructure projects, according to the report.
    • “Gambit dismissed the hackers’ claims of being a new pro-Iranian hacktivist gang, instead attributing their operations to Black Shadow, a group that the Israeli government and private security firms have linked to Iran’s Ministry of Intelligence and Security.”

From the Project Glasswing front,

  • Bleeping Computer reports,
    • “Anthropic has confirmed that it plans to bring Mythos-class models to the general public after delaying the rollout due to security risks to public and private software.” * * *
    • In a blog post, Anthropic confirmed that it plans to release Mythos-class models to the public in the coming weeks, but it has not committed to a specific timeframe.
    • “We’re making swift progress on developing these safeguards and expect to be able to bring Mythos-class models to all our customers in the coming weeks,” Anthropic said in a blog post.
    • “Anthropic says it is already allowing a small number of organizations to use Claude Mythos preview for cybersecurity work, but it is unclear if the same model will be rolled out to the public.
    • “According to the company, the Mythos model shows major improvements in code reasoning and autonomy, far above Claude’s current flagship model, Opus 4.8.”

From the cybersecurity policy and law enforcement front,

  • Beckers Health IT reports,
    • “House Republican leaders are calling on FBI Director Kash Patel to act aggressively to stop cybercriminal groups targeting the healthcare industry.
    • “In a May 28 letter to Mr. Patel, the lawmakers pointed to the sharp increase in healthcare ransomware attacks and data breaches over the past several years that jeopardize patient safety and cost hospitals and health systems millions of dollars.
    • “We strongly encourage continued collaboration between the FBI and healthcare stakeholders, including through public-private partnerships, streamlined reporting mechanisms, and clear guidance that enables hospitals — large and small — to participate effectively in information-sharing initiatives without undue burden,” the legislators wrote.”
  • Cyberscoop relates,
    • “House subcommittee will hold an open hearing next week on how frontier artificial intelligence models are shaping the cybersecurity landscape, for good and for ill.
    • “The June 4 hearing will be the second the Homeland Security Subcommittee on Cybersecurity and Infrastructure Protection has held that was focused at least in part on the subject, following a similar hearing held in December. But unlike at that joint subcommittee hearing, where members also examined other emerging technologies, AI takes center stage next week. * * *
    • “The witnesses will be Sandra Joyce, vice president of Google Threat Intelligence; Chris Meserole, executive director of the Frontier Model Forum; Jack Cable, a former top official at the Cybersecurity and Infrastructure Security Agency and now chief executive officer and co-founder of Corridor Security; and Matthew Guariglia, senior policy analyst at the Electronic Frontier Foundation.”
  • and
    • “The White House has updated rules for federal agencies to keep logs of significant cyber activities in their networks, touting it as a measure to cut back on red tape and focus on how cybersecurity risks have evolved.
    • “The Office of Management and Budget memorandum, released Friday, replaces a 2021 memo signed by then-President Joe Biden. It continues revisions that President Donald Trump has made to federal cybersecurity guidance under his predecessor.
    • “The new memo, M-26-14, nods at the intentions of the earlier memo, M-21-31, saying that “Implementation of that memorandum improved foundational capabilities across agencies” to establish standards for logging and improve agencies’ record-keeping for the purposes of detecting and responding to cyberattacks.” * * *
    • “There have been calls for the idea of updating the 2021 memo, and one observer praised the new version to CyberScoop. Another analyst, however, questioned how much harm the Trump administration might do by rescinding the earlier memo before having all of the new memo’s directives in place.
    • “One directive is for the Cybersecurity and Infrastructure Security Agency to develop a “logging reference architecture” within 90 days that prioritizes the objectives of conducting continuous event monitoring and enabling investigations of forensic analysis after a known or suspected compromise.
    • “Agencies would have another 90 days to submit a logging plan that adheres to those principles. The memo also establishes a new model for measuring agency progress in implementation. Multiple government watchdogs have concluded that agencies weren’t meeting the prior memo’s benchmarks.”
  • Federal News Network adds,
    • “Acting Federal Chief Information Security Officer Mike Duffy wrote on LinkedIn that the new policy “focuses agencies on what matters most: continuous visibility, rapid detection, effective threat hunting and actionable response capabilities.”
    • “And given the recent discovery by Claude’s Mythos of thousands of zero day vulnerabilities in systems that were previously known or not addressed, agencies and industry are being forced to figure out how best to strengthen their partnership against these AI-fueled attacks.
    • “Nick Andersen, the acting director of the Cybersecurity and Infrastructure Security Agency, said he has deep concerns specifically about one type of technology when it comes to cybersecurity vulnerabilities.
    • “The open source community is one that I’m particularly worried about when we start to think about the rapid escalation of vulnerability discovery. But it is going to result in us having to make some really, really hard decisions on the level of investment that’s going to be required,” Andersen said on May 21 at the Cyber Innovation Summit sponsored by the National Security Institute at George Mason University’s Antonin Scalia Law School.”
  • Cyberscoop cautions,
    • “A Department of Commerce inspector general report released Thursday [May 28] found that the National Institute of Standards and Technology has mismanaged a critical cybersecurity vulnerability database through poor planning, inefficient operations, duplicate federal programs, and failure to communicate with users.
    • “The National Vulnerability Database, maintained by NIST since 2005, collects information about computer security flaws and adds details like severity ratings and affected products. This information helps cybersecurity professionals across government and the private sector decide which security problems to fix first. In February 2024, the database’s enrichment contract lapsed, creating a backlog of unprocessed security flaws that has only grown worse.
    • “The report identified the lack of strategic planning as a core problem. NIST leaders admitted they had no long-term plan for clearing the backlog, even as it grew from about 13,000 unprocessed security flaws in June 2024 to over 27,000 by the end of 2025.
  • The American Hospital Association lets us know,
    • “The Cybersecurity and Infrastructure Security Agency May 26 announced a revised schedule for its series of virtual town hall meetings for public input on proposed rulemaking for the Cyber Incident Reporting for Critical Infrastructure Act of 2022. The meetings will now begin June 15. They were originally scheduled for March and April but were not held due to the partial shutdown of the Department of Homeland Security. CISA seeks input to finalize a proposed rule originally issued in March 2024. The proposed rule would require critical infrastructure organizations, including hospitals and health systems, to report certain cyber incidents to CISA within 72 hours and ransom payments within 24 hours, among other mandates. The AHA commented on the rule, calling certain proposed requirements redundant to those from other federal agencies and saying that they may add unnecessary burden to hospitals working to ensure access to needed services during cybersecurity incident response.”
  • CISA notes,
    • “The revised [town hall meeting] schedule is available in the Federal Register. Interested stakeholders may register for the town hall meetings at www.cisa.gov/circia. Any changes or updates to the town halls will be available on www.cisa.gov/circia“
  • Cybersecurity Dive tells us,
    • “The Cybersecurity and Infrastructure Security Agency on Thursday [May 28] warned that hackers targeted software development pipelines in recent weeks and urged security teams to check for potential compromise of their environments. 
    • “CISA referenced two recent campaigns, including the “Megalodon” supply chain attack and a GitHub compromise through a malicious Nx Console Visual Studio Code extension.” * * *
    • “CISA is urging security teams to monitor and conduct audits on their workflow files and activity from contributors. Attention should be paid to suspicious pull requests or direct commits, specifically any coming from an automated account. 
    • “Security teams should revert any unauthorized changes, CISA advised, and check for anything that came in after May 18. 
    • ‘If a compromise is found in connection with a previously compromised Nx Console or GitHub account, CISA suggests the following:
      • “Undertake a forensics review of continuous integration/continuous delivery logs, impacted developer machines and cloud audit trails. 
      • “Rotate or revoke secrets, including credentials, tokens and secrets related to CI/CD pipelines.”
  • The Wall Street Journal informs us,
    • “The FBI’s latest report on internet crime complaints shows cybercriminals are using AI, causing $893 million in losses.
    • “Cryptocurrency investment fraud was the largest source of financial losses, totaling $7.2 billion last year.
    • “Government-impersonation scams increased to over 32,000 complaints last year, aided by AI for sophistication.”
  • Bleeping Computer points out,
    • “A North Carolina man was sentenced to more than 10 years in prison for selling the personal information of over 7 million elderly Americans to Jamaican scammers.
    • “57-year-old Troy Murray (who used the Steve Dixon pseudonym) pleaded guilty in January 2026 to one count of conspiracy to commit wire fraud and was sentenced Thursday to 121 months in prison, three years of supervised release, and ordered to forfeit $5,2 million.
    • ‘Prosecutors said that Murray’s alias was so widely known among Jamaican scammers that it was referenced in a 2022 song lyric by a Jamaican musical artist.
  • and
    • A Romanian national was sentenced this week to 56 months in federal prison for breaking into an Oregon state government computer network and fr cyberattacks targeting dozens of other U.S. victims.
    • 46-year-old Catalin Dragomir (who used the online handle “inthematrixl”) of Constanta, Romania, pleaded guilty on February 19 to one count of aggravated identity theft and one count of obtaining information from a protected computer.
    • The charges carried a maximum of five years in prison for the computer intrusion count, followed by a mandatory consecutive two-year term for the identity theft count, a fine of $250,000, and three years’ supervised release. The court also ordered Dragomir to forfeit approximately 23 Monero (XMR), a cryptocurrency, valued at roughly $8,500.

From the cybersecurity breaches and vulnerabilities front,

  • Bleeping Computer reports,
    • “The ShinyHunters extortion gang stole personal information from 4.9 million accounts after hacking the U.S. telecom giant Charter Communications in early April, according to data breach notification service Have I Been Pwned.
      “Charter has over 92,000 employees and provides internet, mobile, video, and voice services to more than 32 million customers and over 57 million homes in 41 states across the U.S. through its Spectrum brand.
      “The company confirmed the breach earlier this week, saying that the attackers did not steal sensitive personal customer information and that it had alerted authorities about the incident.”
    • * * * “After the company refused to pay the ransom demanded by ShinyHunters to have the stolen data returned and destroyed, the cybercrime group leaked the documents stolen from Charter’s Salesforce instance on their dark web leak site.
    • “Have I Been Pwned analyzed the leaked data and confirmed that the incident affected 4.9 million accounts, whose names, email addresses, job titles, phone numbers, and physical addresses were stolen.
    • “The group later published the data, which exposed 4.9M unique email addresses along with names, phone numbers and physical addresses,” Have I Been Pwned said. “A subset of approximately 85k records originating from an internal employee directory also included job titles.”
    • “The FBI has recently advised ShinyHunters’ victims not to give in to the gang’s ransom demands, after previously warning that doing so cannot guarantee that threat actors won’t attempt to sell the stolen data to other cybercriminals or extort them again.
  • and
    • “Threat actors are abusing ChatGPT’s content-sharing feature to display fake OpenAI outage pages that direct users to download malware disguised as the ChatGPT desktop application.
    • “The “LLMShare” campaign, discovered by Push Security, uses Google ads to direct users searching for ChatGPT to a malicious shared ChatGPT page hosted on chatgpt.com, allowing the attack to be delivered through a legitimate OpenAI domain.
    • “Users who click the advertisement are taken to a legitimate ChatGPT shared page, but instead of seeing a chat conversation, they are presented with a rendered outage notice claiming the web version is unavailable and that they should download the desktop application instead.”
  • Security Week relates,
    • “The infamous extortion gang Silent Ransom Group (SRG) has been impersonating IT support in a fresh campaign targeting law firms, the FBI warns.
    • “Active since at least 2022, SRG has been targeting law firms in the US since at least 2023, mainly through callback phishing emails and social engineering calls, claiming to aid victims in canceling subscription fees.
    • “In a May 2025 alert, the FBI warned of SRG’s phishing emails containing links to remote access software that allowed the attackers to quickly exfiltrate data from the victims’ systems.
    • “In attacks observed this year, the threat actor has updated its tactics, now posing as an employee from the victim’s IT department.” * * *
    • “To prevent SRG attacks, organizations are advised to verify the credentials of all individuals with access to company assets, limit access to sensitive data, train employees to identify phishing attempts, and establish clear policies for IT support communication and authentication.
    • “Backing up all company data, implementing phishing-resistant multi-factor authentication (MFA), blocking access to commonly exploited ports, and disabling remote access and permissions for external drive installation should also prevent intrusions and the loss of sensitive and confidential data.”
  • Cybersecurity Dive tells us,
    • “Nearly all executives are confident their employees are using AI responsibly, but shadow AI is creeping its way into organizations, an Okta survey released Wednesday found. More than half of employeesreported they’re using personal AI tools without approval, the security platform provider learned in surveying nearly 300 tech executives and 500 knowledge workers along with market research firm Apprize360.
    • “Workers reported using unapproved AI tools for productivity reasons, saying they allow the tools access to internal messages, HR-related information and confidential company documents. The practice is heightening security risks, as 58% of executives said their organization had an AI-related security incident or a close call last year, according to the report. 
    • “Lack of clarity in AI usage policies or banning personal AI tools can actually increase shadow AI use, said Harish Peri, Okta’s SVP and GM for AI security, in an email. “By taking a more collaborative approach with employees, leaders can offer sanctioned, enterprise-grade alternatives to the unapproved tools that teams are using.”

From the ransomware front,

  • Industrial Cyber reports,
    • “The Federal Bureau of Investigation (FBI) disclosed that about 25 ransomware groups used a criminal VPN service known as ‘First VPN Service’ to conduct network intrusions, scanning operations, botnets, denial-of-service attacks, and scams. The service has been active since around 2014 across 32 exit nodes in 27 countries. It affects organizations by enabling ransomware groups and other cybercriminal actors to conduct network intrusions, reconnaissance, credential abuse, denial-of-service attacks, and broader malicious operations.
    • “At least 25 ransomware groups, such as Avaddon Ransomware, have used First VPN Service infrastructure to perform network reconnaissance and intrusions,” the FBI wrotein a recent FLASH advisory. “First VPN Service IP addresses have been used for scanning activity, botnets, denial of service attacks, scams, and hacking. First VPN Service was almost exclusively advertised in known criminal dark web forums such as Exploit[.]in and XSS[.]is, two of the most prominent Russian-language online forums which provide marketplaces for cyber criminals to buy and sell unauthorized access to computer systems, stolen personal identifying information, hacking tools, and contraband. This reporting applies solely to the First VPN Service and does not extend to other VPN providers with similar naming.” 
    • “The revelation came alongside a coordinated international takedown of the service, led by French and Dutch cybercrime units with support from Ukraine, the U.K., Switzerland, and Luxembourg. It follows from the findings that the VPN was marketed almost exclusively on prominent Russian-language dark web forums used by cybercriminals to trade stolen data, hacking tools, and unauthorized access to systems.”
  • Morphisec tells us “How AI is Changing Ransomware — and Why It’s Faster, Smarter, and Harder to Detect.” 
    • “AI-driven ransomware is still in its early stages, but the direction is clear. Threats are becoming:   
      • “faster  
      • “more adaptive
      • “more autonomous  
      • “harder to observe  
      • “increasingly resistant to detection    
    • “Organizations that continue relying solely on reactive security models will face growing exposure as attack timelines shrink, and visibility gaps expand. The future of cybersecurity will not be defined by who can detect threats fastest. It will be defined by who can prevent them from executing at all.”   
  • Tech Radar adds,
    • “There is a glaring misconception at the heart of cybersecurity that cyber-attacks are targeted at specific organizations or sectors. But while certain sectors do receive more than their fair share of attacks, this isn’t due to deliberate targeting; like any business, it’s driven by money.
    • “Threat groups are largely driven by financial gain, with actors looking to get the most ‘bang for their buck’. Targeting vulnerabilities that don’t just give them access to one organization, but multiple, to grow their potential revenue opportunities.
    • “And at the moment, organizations are leaving far too many of these vulnerabilities open for exploitation.”

Cybersecurity business and defenses front,

  • Cybersecurity Dive reports,
    • “IBM will spend $5 billion to help find and fix vulnerabilities in open-source software packages used throughout the business world, the company announced on Thursday [May 28].
    • “Through Project Lightwell, IBM will create “a trusted enterprise clearinghouse combined with a global force of engineers to identify and fix vulnerabilities at scale,” using AI to validate and test the patches before deployment, the company said. Businesses will be able to subscribe to the patching program for automated deployment of fixes that integrates with their existing life cycle management processes.
    • “Open source is the backbone of today’s digital economy and the foundation of modern AI, and we are at an inflection point in how it is built, secured, and scaled,” IBM CEO Arvind Krishna said in a statement. “This is about strengthening trust in the systems that power business, government, and society.”
  • Security Week relates,
    • “Google Cloud this week announced an always-on autonomous platform designed to protect enterprises from the rising wave of AI-powered cyberattacks.
    • “The new Google AI Threat Defense cybersecurity solution leverages AI to identify machine-powered threats faster and stop them before they can do harm.
    • “According to Google, the platform continuously prioritizes critical real-world risks and can help organizations implement defenses that predict attack paths and proactively deploy remediation.
    • “Google AI Threat Defense combines Mandiant’s frontline and incident response experience with Wiz’s cloud security platform (recently acquired by Google) and Gemini’s reasoning and code remediation capabilities powered by Gemini and CodeMender.
    • “By connecting real-world exposure directly to autonomously creating and prioritizing patching, AI Threat Defense helps organizations actively predict attack paths, prioritize the most significant threats, and deploy verified fixes faster than adversaries can exploit them,” Google says.”
  • and
    • “Anthropic has announced two new security features for its Claude AI: a self-hosted sandbox and a new security guidance plugin.
    • “The sandbox, currently in public beta, was announced at Anthorpic’s Code w/ Claude event in London this week.
    • “According to the company, Claude Managed Agents can now operate in a user-controlled sandbox connected to the user’s private MPC servers. 
    • “Tool execution moves to an environment you configure—your own infrastructure or a managed provider like Cloudflare, Daytona, Modal, or Vercel—while the agent loop that handles orchestration, context management, and error recovery stays on Anthropic’s infrastructure,” Anthropic explained. 
    • “It added, “Your network policies, audit logging, and security tooling apply, files and repositories don’t leave your perimeter, and you control compute sizing and the runtime image for compute-heavy work.”
    • “Separately, the company unveiled a security guidance plugin for Claude Code, designed to help developers detect and fix vulnerabilities as they write code.”
  • Cyberscoop informs us,
    • “CrowdStrike has dismantled the Glassworm botnet in an operation aided by Google and Shadowserver, stripping the operators’ access to infrastructure that helped threat actors infect hundreds of pieces of open-source software with malware since early 2025, the company said Tuesday [May 26]. 
    • “The coordinated effort involved the simultaneous takedown of four attacker-controlled servers that were designed to obscure the botnet’s operations and remain resilient against disruptions.
    • “CrowdStrike and partners took down infrastructure, severed access to the botnet’s most critical services, impeded operation momentum and slowed the attackers’ ability to scale, Adam Meyers, senior vice president of counter adversary operations at CrowdStrike, told CyberScoop.”
  • and
    • “Security researchers chained together five separate weaknesses in the popular workflow automation service Zapier that, if first discovered by a malicious actor, could have granted access to millions of user accounts and the systems those accounts connect to.
    • :The flaws, disclosed by security firm Token Security, did not require malware or insider access. The only prerequisite, according to the company’s report, was a free Zapier account. From there, researchers chained together weaknesses that, if taken individually, would have looked routine, but together opened a path to one of the most widely used services of the modern internet.
    • “Zapier’s software can be configured to move data between email, customer-relationship tools, payment processors, calendars, code repositories and thousands of other applications. Zapier says it supports more than 8,000 third-party integrations and has millions of users, which means breaking into Zapier could escalate into a wide-ranging supply-chain attack.” * * *
    • “The episode lands at a moment when automation platforms and artificial-intelligence tools are increasingly being granted the standing authority to act on behalf of users across dozens of services at once. Token Security’s researchers argued that the weaknesses they found were not unique to Zapier. Each link in the chain, they said, was a well-documented kind of mistake. The vulnerability was the chain itself, and the same pattern, they warned, almost certainly exists at other companies that have not yet looked.
    • “Zapier says the issues have been fixed and no further action is required. But the researchers suggested organizations with heightened sensitivity review their automation logs for anything they did not create, and consider reauthorizing Zapier connections to particularly sensitive systems.
    • “You can read the full research report on Token Security’s website.” 
  • Tech Target points out
    • “The unified platform versus best-of-breed tools debate continues as security teams struggle with integration challenges, alert fatigue and limited resources. Does buying software from individual vendors still make sense, or does that approach only further complicate today’s distributed networks? The pressure is prompting a fresh look at unified security platforms as a way to reduce complexity and costs, improve visibility and regain control.”
  • An SC Media commentator identifies “seven identity security best practices for the Agentic AI era.”
    • “Execute regular identity security risk assessments: Leverage tools that can clearly show what AI agents operate in our environment, including those that are operating as shadow IT. This analysis should put risks in clear context, including agent security posture, and potential escalation paths.
    • “Encrypt credentials: Put them in a secure vault, with automatic key rotation to make it harder to steal or reuse valid credentials.
    • “Restrict remote access to systems: Use leverage tooling that can perform automated credential injection from the company’s vaults to prevent adversary-in-the-middle attacks.
    • “Use workload identity to avoid long-lived tokens: Also use scoped permissions, whether OAuth-based or otherwise, to reduce the “blast radius” of stolen credentials.
    • “Limit permissions on endpoints with endpoint privilege management tools: Default permissions to “standard user” and set up policies that limit what local agents can do on those systems. Remove standing policies and replace them with JIT or time-limited policies and permissions.
    • “Implement IP allowlisting: This will reject AI agent requests coming from non-authorized locations.
    • “Log and audit all privileged behavior: Do this in all systems, whether that’s through tools such as session logs, shipping event logs to a SIEM, or using anomalous behavior analysis tools in the SOC.”
  • Here is a link to Dark Reading’s CISO Corner.

Holiday Weekend Update

“Simplicity is a virtue”

From Washington, DC,

  • Congress is taking a State / District work break this week following Memorial Day.
  • The Office of Management and Budget’s Office for Information and Regulatory Affairs has completed its review of the No Surprises Act Independent Dispute Resolution final rule, which indicates that this significant final rule will be published in the Federal Register this week.

From the judicial front,

  • USA Today, via Yahoo Finance, reports
    • “CVS sued Tennessee state officials on May 22 to block legislation the pharmacy giant said would force the closure of the chain’s 136 Tennessee pharmacy locations.
    • “CVS filed the U.S. District Court lawsuit in Nashville after Tennessee Gov. Bill Lee signed legislation to prohibit companies from owning both pharmacy benefit managers and retail pharmacies. The Tennessee legislation takes effect July 1, 2028.”

From the public health and medical /Rx research front,

  • STAT News reports,
    • “Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial, an early but encouraging test of whether a one-time treatment may one day help people seeking to lower their LDL, or “bad,” cholesterol.
    • “Lilly acquired the therapy, VERVE-102, in its $1 billion buyout of Verve Therapeutics last year. Executives tout it as a potential treatment to broadly prevent heart disease, the world’s leading killer, as many patients struggle to stay on existing, more conventional medicines for reducing cholesterol levels.
    • “There were no treatment-related serious adverse events in the Phase 1 study — a notable finding, given that Verve had to shelve its first candidate due to safety concerns. 
    • “The data were simultaneously published in the New England Journal Medicine and presented at the European Atherosclerosis Society in Athens.
    • “Lilly now plans to begin a Phase 2 trial in an unspecified number of patients. It will likely need to then run Phase 3 trials in thousands of patients for the treatment to earn approval.” 
  • The Washington Post relates,
    • “Pancreatic cancer is an exquisitely cruel diagnosis, leaving only 13 percent of people alive after five years. But in the early 1980s, scientists discovered a weakness — a mutated protein called KRAS — that spurred the aggressive growth and spread an array of tumors. In pancreatic cancer, it would turn out to be a key driver of nearly every case. 
    • “There was just one problem. The KRAS protein they needed to block was flat and smooth, without the crevices and cracks, pockets and sockets that a drug needs to get a toehold.
    • “No longer.
    • “In the span of a few weeks, the conventional wisdom on pancreatic cancer and KRAS has been upended. In April, biotech company Revolution Medicines announced that its experimental pill, called daraxonrasib, had notched an unprecedented success — patients lived for 13 months, twice as long as those given regular chemotherapy. The full details will be presented next weekend at the American Society of Clinical Oncology meeting in Chicago, but federal regulators have already expanded access to the drug while it is being reviewed.
    • “It’s the start of a huge wave for this disease,” said Eileen O’Reilly, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center. Following behind are other drugs that may work better and the potential to use the approach against lung and colorectal cancers.”
  • Medscape informs us,
    • “GLP-1 receptor agonists, like semaglutide, are gaining importance in liver disease treatment, notably for metabolic-associated steatohepatitis (MASH) and alcohol use disorder (AUD), offering benefits beyond weight loss, including potential hepatoprotection.
  • and
    • “CAR T-cell therapy, initially for cancer, shows promise in treating autoimmune diseases like multiple sclerosis. While offering hope, it poses risks and uncertainties, including potential long-term side effects and high costs, necessitating further research.”

From the U.S. healthcare business front.

  • Beckers Payer Issue points out,
    • ‘Point32Health reported an adjusted net income of $248 million in the first quarter, a sharp reversal from a $21 million adjusted net income a year prior.
    • “The insurer, parent company of Harvard Pilgrim Health Care and Tufts Health Plan, said the Q1 results included an operating income of $86 million, investment income of $6 million, and a gain from the sale of its Integra Partners subsidiary. Revenues were $2.4 billion and membership was nearly 2 million.
    • “In the first quarter of 2025, the company reported an operating loss of $39 million and investment income of $61 million, on revenues of $2.4 billion and membership of approximately 2 million.
    • “While we are optimistic for the remainder of the year, we recognize that medical and pharmaceutical cost trends remain volatile and will continue to present challenges,” CFO Michael Marrone said.’
  • Per a Health Care Cost Institute news release,
    • “Conventional wisdom and economic theory suggest that more competition means lower prices. In health care, there is longstanding evidence that geographic areas with less competition among hospitals are associated with higher negotiated commercial prices. Regulators and researchers use the Herfindahl-Hirschman Index (HHI) to measure market concentration at a geographic area. HHI can range from 0 (competitive market) to 10,000 (monopoly market). Hospital markets that are considered “highly concentrated,” (HHI greater than 2,500) generally means that there are a limited number of hospitals or health systems that dominate the market. There also is evidence in the economic literature that geographic areas that have a limited number of insurance companies are associated with lower negotiated commercial prices. These insurance markets are considered “highly concentrated.” 
    • “In this cross-sectional analysis of 2022 data, we examine the impact of competition on prices across the US.  Specifically, we compared a measure of hospital prices – the inpatient hospital price index from HCCI’s Health Cost Landscape – in areas with varying levels of hospital and insurance company concentration. We focused on inpatient hospital prices because they are most directly related to hospital and health insurance market dynamics.      
    • “We find that inpatient hospital prices are the highest in metro areas where hospital markets are very highly concentrated (least competitive) and insurance markets were moderately concentrated (the most competitive among the markets in the Landscape). Inpatient hospital prices in these metro areas were, on average, about 25% higher than the national median in 2022. Inpatient prices were lowest, in contrast, in metro areas where hospital markets were the least concentrated but the health insurer market was highly concentrated.  Among metro areas where health insurers are highly concentrated and hospitals are least concentrated, inpatient hospital prices were about 10% lower than the national median.”  
  • Kaufmann Hall lets us know,
    • “[H]ospitals across the country are facing difficulty placing patients into SNFs and other post-acute sites of care, delaying discharge of medically ready patients. Post-acute access constraints are structural and systemic and are reshaping hospital performance—including hospital margins, capacity, throughput, quality metrics, staff morale, and patient experience. Health systems that proactively redesign their post-acute strategy, particularly through aligned SNF and other post-acute partnerships, can materially improve performance across these dimensions and mitigate risk, while also equipping these facilities with the alignment and financial resources necessary to thrive.” * * *
    • “SNF bed supply fell 2.5% between 2019 and 2024, creating a sustained imbalance between supply and demand. As this imbalance persists, access challenges are likely to intensify rather than normalize. Hospitals in regions with SNF bed under capacity tend to experience greater mean length of stay, percentage of stays 28 days or more, and median distance traveled to admitting SNFs.” * * *
    • “Ultimately, improved SNF access is driven by alignment, incentives, and operating expertise—not [hospital] ownership alone. 
    • “Several health systems, such as Stanford Health Care, Scripps Health, and UC Davis Health, have also had success with the bed reservation / bed lease program as an aligned alternative for post-acute care access and patient throughput.”
  • Healthcare Dive tells us,
    • “Private equity-owned hospital operator Quorum Health plans to transition to nonprofit status this year through a deal with Healthside Partners.
    • “The definitive agreement announced Thursday is meant to help put Quorum, which has struggled to recover following its bankruptcy in 2020, on more stable financial footing through access to the tax and funding benefits nonprofit hospitals receive.
    • “The deal appears to be structured as straight asset transfer, wherein the nonprofit system Healthside will acquire Quorum’s assets without inheriting its liabilities and obligations. Quorum will remain a separate company that will then be dissolved, a spokesperson for the system said. The transition is expected to close this fall.”

Cybersecurity Saturday

From the War with Iran front,

  • Cybersecurity Dive reports yesterday,
    • “Iranian government-backed hackers are using spear-phishing attacks and remote access Trojans (RATs) to spy on “high-value sectors” in the U.S. and the Middle East as part of Tehran’s response to the U.S.-Israeli war, according to Palo Alto Networks.
    • “The company’s Unit 42 researchers recently discovered six new RATs that an Iran-linked group the researchers call Screening Serpens has used for espionage purposes. The group “has increased its operations” since the war began, the researchers said, and malware metadata suggests that it has attacked “targets across the U.S., Israel and the [United Arab Emirates] as well as two additional Middle Eastern entities.”
    • “Screening Serpens — which other researchers call UNC1549, Smoke Sandstorm and Nimbus Manticore — has “consistently set its sights on high-value sectors,” Palo Alto Networks said, especially in the aerospace, defense and telecommunications industries.
    • “A defining characteristic of these recent campaigns is the deep personalization of the attackers’ lures,” researchers wrote. “By leveraging tailored social engineering tactics, including fake job requisitions and spoofed video conferencing meeting invitations, the attackers lure victims into initiating the infection chain, thereby exposing their organizations to further exploitation.”
  • Industrial Cyber adds,
    • “Ransomware groups are increasingly being used as proxy weapons in geopolitical cyber warfare, enabling nation-states to exert pressure on their adversaries while maintaining plausible deniability. What used to be financially motivated cybercrime and targeting can now influence operations and cause operational disruption. While the change has been incremental, it has been unmistakable. Criminal groups, ideological hacktivists, and state-aligned adversaries are converging and sharing environments, infrastructure, tactics, techniques, and procedures (TTPs), access brokers, and, at times, even strategic objectives.
    • “Operations linked to Iran demonstrate the sprawl between cybercrime, espionage and industrial sabotage as ever closer. A recent investigation exposed claims by pro-Iran hackers that they altered on-the-ground conditions to target critical wheat reserves, demonstrating how cyber activity can directly affect food security and industry. Once the contact is made, these adversaries can choose how and when to attack.”

From the Project Glasswing front,

  • Anthropic offers a look back at the project’s first month.
  • The Wall Street Journal adds,
    • “Anthropic is letting Mythos users [participating in Project Glasswing] share cybersecurity threats with others who may face similar vulnerabilities.
    • “Anthropic modified its previous stance amid concerns that limiting access to the information could hurt smaller companies.
    • “The new policy highlights challenges facing artificial-intelligence companies that are restricting access to their best models.’

From the cybersecurity policy and law enforcement front,

  • Cyberscoop reports,
    • “Two cybersecurity-focused members of Congress agreed Thursday [May 21, 2026] that reductions to the Cybersecurity and Infrastructure Security Agency have done too much damage to an agency essential to defending civilian networks against foreign adversaries.
    • “Rep. Don Bacon, R-Neb., and Rep. James Walkinshaw, D-Va., spoke during a panel at the National Cyber Innovation Forum. Despite representing different parties, and serving on different congressional committees, the two lawmakers offered closely aligned assessments of CISA’s role and the consequences of recent cuts.” * * *
    • “In the model both lawmakers endorsed, they pushed for CISA to play more of a role after an intrusion, helping affected entities restore their networks while the FBI works to identify the source. Walkinshaw said advanced artificial intelligence expands the attack surface and makes that kind of centralized support more important.”
  • The Wall Street Journal relates,
    • “State cybersecurity officials urged the federal government on Thursday to roll back cuts to cybersecurity programs, arguing that deteriorating federal support weakens defenses just as artificial intelligence and nation-state belligerence are introducing significant new threats.
    • “Technology and cyber officials from New York, Florida and Tennessee told a House Homeland Security Committee hearing that states must now defend against advanced threats as federal backing diminishes.
    • “The witnesses cited the pending expiration of the State and Local Cybersecurity Grant Program, significant budget and workforce cuts to federal agencies and new limits on the information-sharing platforms that state governments rely on to track threats.”
  • Cyberscoop adds,
    • “Securing some of the open-source technology that serves as the backbone for all modern digital infrastructure is going to require some “hard decisions” amid a wave of malware attacks, the leader of the Cybersecurity and Infrastructure Security Agency said Thursday [May 21, 2026].
    • “The open-source community is one that I’m particularly worried about when we start to think about rapid escalation of vulnerability discovery,” acting director Nick Andersen said, referencing a cartoon about how key technologies that underpin the internet are often maintained by a single person.” * * *
    • “CISA has been working with industry and others “to modify our approach to vulnerability management, modify our approach to coordinated vulnerability disclosure, modify our approach to remediation, with the explicit understanding that we’re just not going to be able to keep up using traditional mechanisms,” Andersen said, speaking at the National Cyber Innovation Forum in Washington, D.C.
    • “The government and private sector can work together to identify the biggest threats and then give them the right level of attention, he said. On the federal government side, that means working to get a full picture of the extent of reliance on open-source technologies.” 
  • and
    • “President Donald Trump said he would postpone the release of an executive order that would set up a 90-day testing and vetting regime for frontier AI models, hours before the White House was set to publicly announce the signing. 
    • “Speaking to reporters in the Oval Office Thursday [May 21, 2026], Trump said he opted to delay the order “because I didn’t like certain aspects of it” and expressed concerns that it could harm U.S. AI industry competition with countries like China. 
  • Cyberscoop tells us,
    • “Authorities arrested and unsealed charges against a Canadian man accused of running Kimwolf, one of the most far-reaching DDoS botnets on record, the Justice Department said Thursday.
    • “Jacob Butler was arrested Wednesday [May 20, 2026] in Ottawa, Canada, and awaits extradition to the United States where he is charged with aiding and abetting computer intrusions and, if convicted, faces up to 10 years in prison.
    • “Investigators said the 23-year-old, also known as “Dort,” was a principal administrator of Kimwolf, a variant of the record-setting Aisuru DDoS botnet that spread like wildfire and eventually took over more than 2 million Android TV devices after its operators figured out how to abuse residential-proxy networks for local control.”
  • and
    • “European authorities took down a prominent virtual private network service and arrested the alleged administrator behind an operation that cybercriminals used to steal data, commit fraud and ransomware attacks, Europol said Thursday [May 21, 2026]. 
    • “First VPN, which was promoted on Russian-speaking cybercrime forums, gained popularity for providing services that allowed users to hide their infrastructure and identities. Officials said the service was entrenched in the cybercrime world and appeared in almost every major recent cybercrime investigation aided by Europol.
    • “For years, cybercriminals saw this VPN service as a gateway to anonymity,” Edvardas Šileris, head of Europol’s European Cybercrime Centre, said in a statement. 
    • “They believed it would keep them beyond the reach of law enforcement,” Šileris added. “This operation proves them wrong. Taking it offline removes a critical layer of protection that criminals depended on to operate, communicate and evade law enforcement.”
  • Security Week adds,
    • “Authorities in North America and Europe have participated in a law enforcement operation to disrupt First VPN, a popular cybercrime service used for ransomware and other attacks.
    • “According to the FBI, First VPN has been active since 2014, providing 32 exit nodes across 27 countries at the time of its disruption. The service, advertised on Russian-language dark web cybercrime forums, has been used by at least 25 ransomware groups for network reconnaissance and intrusions.”
    • “Bitdefender, which was involved in the takedown, pointed out that the 506 users are a subset of First VPN’s customer base, and investigators will determine which of them can be linked to criminal operations. 
    • “Some will be traced to known ransomware groups. Others will reveal fraud operations, data theft campaigns, or cybercrime-as-a-service infrastructure we didn’t know existed,” Bitdefender said.
    • “New anonymization services will appear. The economic demand hasn’t changed. But each takedown shortens the operational window of the next service and raises the barrier for actors who relied on turnkey solutions,” the cybersecurity firm added. “First VPN advertised itself as a service criminals could trust to keep them beyond law enforcement’s reach. The operation proved that claim wrong, and every actor evaluating the next anonymization service now knows the same risk exists.”

From the cybersecurity breaches and vulnerabilities front,

  • Health Exec reports,
    • “The largest public health system in the U.S. confirmed in a filing with the Department of Health and Human Services that a data breach on its network impacted 1.8 million patients, exposing their personal data to hackers.
    • “The data breach, which was said to have lasted for months, was revealed by NYC Health + Hospitals in March. At the time, the health system said it first discovered “suspicious activity” on its network in February, at which time it moved to “immediately” secure its systems from access by the unauthorized third-party.
    • “An investigation found cybercriminals had been inside its IT infrastructure since November 2025, stemming from a breach on an unnamed vendor the organization contracts with for services.”
  • Dark Reading relates,
    • “Defenders are dealing with an influx of vulnerabilities like never before, and patch prioritization has never been more critical, according to Verizon Business’s 2026 Data Breach Investigations Report (DBIR). This year’s report confirmed several ongoing trends on the vulnerability exploitation and around threat actors abusing AI, for example — but the 2026 DBIR more broadly promotes sticking to the cybersecurity fundamentals as the industry undergoes massive change.
    • “And indeed, defenders in the past year have been tasked with handling everything from self-replicating worms infesting software components to preparing for large language models (LLMs) that can supposedly discover critical zero-day vulnerabilities all on their own.
    • “Most striking in the DBIR might be the statistics that show vulnerability exploitation to be the most common initial access vector for breaches last year, up 31% from the previous year. Meanwhile, only 26% of critical vulnerabilities (defined as those in CISA’s Known Exploited Vulnerability catalog) were fully remediated by organizations in 2025, compared to 38% the previous year. Just over half (58%) were partially remediated last year, and 16% remained unaddressed.” * * *
    • “While organizations perhaps got worse at patching, Verizon also observed a dramatic increase in the number of vulnerability detections observed year over year, likely driven by AI-assisted bug hunting. “There were 68.7 million records in the 2022 dataset and 527.3 million in 2025 — almost eight times the volume,” the DBIR reads.”
  • The HIPAA Journal tells us,
    • “Verizon has published its 2026 Data Breach Investigations Report, which shows that the healthcare sector continues to be targeted by cybercriminal groups. The sector is having to contend with sustained multi-vector attacks, including ransomware, unpatched vulnerabilities, and human error. Regardless of the cause, the attacks are putting patient privacy, safety, and care at risk.
    • “Verizon tracked 1,492 healthcare incidents for its 2026 report, including 1,438 confirmed data disclosures, a majority of which were due to ransomware-driven system intrusions achieved through multiple attack vectors, including the exploitation of vulnerabilities (20%), phishing attacks (14%), stolen credentials (11%), and employee errors (11%). Threat actors are being given far too big a window of opportunity to exploit known vulnerabilities. Verizon found that in 2025, only 26% of critical vulnerabilities were fully remediated, with a median time for resolution stretching to 43 days. In healthcare, where complex legacy systems are the norm, the window of opportunity is greater, giving threat actors a wide attack window.
    • “While external actors accounted for the majority of incidents, insider breaches remain common in healthcare. Internal actors were behind 19% of breaches. As Verizon notes, human error continues to be a chronic source of breaches. The human element was involved in 54% of incidents, including misconfigurations, misdirected communications, the loss/theft of unencrypted devices, and poor cyber hygiene.
    • “The most common human-related cause of healthcare data incidents was misdelivery, which accounted for around 40% of incidents, followed by loss incidents at around 25%, and misconfigurations at around 20%. While greater investment in cybersecurity will help to address the 81% of breaches due to external actors, security awareness training plays an important part in preventing data breaches. Employees need to be made aware of security fundamentals and be taught the importance of practicing good cyber hygiene. Social engineering was the third main cause of healthcare breaches in 2025, the majority of which were due to phishing, followed by pretexting – these attack techniques need to be covered in depth in training courses.”
  • CISA added ten known exploited vulnerabilities (KVEs) to its catalog this week.
  • Cybersecurity Dive adds,
    • “The Cybersecurity and Infrastructure Security Agency is now letting security experts nominate vulnerabilities to the agency’s Known Exploited Vulnerabilities catalog.
    • “CISA on Thursday [May 21, 2026] published a form that technology vendors, independent researchers and anyone else can use to warn CISA that hackers are exploiting a vulnerability and it should be added to the KEV.
    • “This new reporting capability enhances CISA’s ability to identify, validate, and quickly share critical threat information,” Chris Butera, CISA’s acting executive assistant director for cybersecurity, said in a statement. “Early detection and coordinated vulnerability disclosure are among the most powerful tools we have to reduce risk at scale.”\
  • and
    • “Hackers stole data from thousands of GitHub repositories, the code-hosting giant said on Tuesday [May 19, 2026].
    • “While we currently have no evidence of impact to customer information stored outside of GitHub’s internal repositories (such as our customers’ enterprises, organizations, and repositories), we are closely monitoring our infrastructure for follow-on activity,” the company said in a post on X.
    • “On Wednesday [May 20, 2026], the company confirmed that attackers had compromised roughly 3,800 repositories after a GitHub employee used a malware-infected Visual Studio Code extension.
    • “We continue to analyze logs, validate secret rotation, and monitor for any follow-on activity,” GitHub said.”
  • Cyberscoop informs us,
    • “The FBI is warning organizations and defenders about Kali365, a growing phishing-as-a-service platform that retrieves Microsoft 365 access tokens, issuing a public service announcement Thursday [May 21, 2026]. 
    • “The toolkit bypasses multi-factor authentication and abuses OAuth device code authorizations via phishing lures impersonating common enterprise services. This technique grants cybercriminal-controlled applications access to Microsoft 365 accounts, opening victims up to a host of follow-on malicious activity, including data theft, fraud, extortion and ransomware attacks.
    • “Kali365 is one of many rapidly emerging device-code phishing tools, which are gaining popularity as a more effective means for cybercriminals to circumvent security controls while abusing legitimate Microsoft device authorization pages, according to researchers.
    • “Instead of gaining access to accounts via phishing kits that steal credentials and second-factor authentication codes, device-code phishing platforms connect a malicious app to a legitimate account with a single code. The process requires fewer steps and less interaction with the user, but victims do have to copy-and-paste a code generated by the Kali365 platform to grant access.”
  • Cyber Insider points out,
    • “Hidden audio commands can hijack AI voice assistants and transcription tools without users hearing anything unusual, according to new research set to be presented at the IEEE Symposium on Security and Privacy next week.
    • “The study shows that carefully crafted audio clips can elicit unauthorized actions from audio-language models (LALMs), including downloading files, sending emails, and performing web searches.
    • “The attack, dubbed “AudioHijack,” was developed by researchers from Zhejiang University, Nanyang Technological University, and the National University of Singapore. The team describes the attack as a form of “auditory prompt injection,” in which malicious instructions are embedded in ordinary audio using adversarial perturbations that remain nearly imperceptible to human listeners.
    • “Large audio-language models are increasingly powering voice assistants, meeting transcription services, customer support bots, and multimodal AI systems capable of both understanding and generating speech. Some platforms can also interact with external tools and services, allowing them to search the web, operate apps, or execute commands on behalf of users. According to the researchers, these capabilities significantly expand the attack surface.
    • “Attackers could potentially hide malicious prompts inside music, videos, voice notes, or even live conversations uploaded to AI services. The paper also describes scenarios in which hidden audio could be injected into Zoom meetings or multimedia content processed by AI assistants.”
  • The Hacker News notes,
    • “In February 2026, a phishing-as-a-service (PhaaS) platform called EvilTokens went live. Within five weeks, it had compromised more than 340 Microsoft 365 organizations across five countries. 
    • “The targets of the platform received a message asking them to enter a short code at microsoft.com/devicelogin and complete their normal MFA challenge, then walked away believing they had verified a routine sign-in. They had actually handed the operator a valid refresh token scoped to their mailbox, drive, calendar, and contacts, with the lifespan of a tenant policy rather than a session.
    • ‘The operator never needed a password, never tripped an MFA prompt, and never produced a sign-in event that looked like an intrusion. The attack succeeded because the OAuth consent screen has become an instinctive click, and the controls built to stop credential phishing do not look at the consent layer.
    • “Security researchers call the resulting condition consent phishing or OAuth grant abuse. The phishing click that mattered last decade handed over a password. The phishing click that matters now hands over a refresh token, and it sits structurally below the identity controls most organizations still treat as the perimeter.”

From the ransomware front,

  • Sophos reports,
    • “SophosLabs analysts investigated WantToCry ransomware attacks that involved the threat actors abusing the Server Message Block (SMB) service for initial access and then exfiltrating files to attacker-controlled infrastructure for remote encryption. The detection surface is significantly reduced because WantToCry operates without local malware execution, and there is no post-compromise activity beyond exfiltrating files and rewriting them to disk.
    • “The WantToCry name appears to be a reference to the notorious WannaCry (also known as WCry) ransomware worm, which propagated via a vulnerability in SMB at the start of 2017. While WantToCry is not self-propagating and there is no evidence to suggest that the two operations are connected, organizations with internet-exposed SMB services are similarly at risk.” * * *
    • “As with all ransomware activity, prevention remains key to mitigating the threat of remote ransomware operations like WantToCry. Preventive measures include disabling the SMBv1 protocol across the organization, removing “guest” or anonymous SMB access, and blocking inbound SMB traffic (ports TCP/139 and TCP/445) at all internet-facing firewalls. Additionally, it is important to ensure that backups cannot be accessed via SMB protocols.
    • “Organizations should also implement network-level controls and file content monitoring to address this attack methodology effectively. A tool like Sophos CryptoGuard can identify, block, and roll back encryption activity performed via SMB protocols.
    • “WantToCry relies on weak authentication and internet exposure rather than on software vulnerabilities or malware delivery mechanisms. Extended detection and response (XDR) solutions can identify reconnaissance and brute-force attempts against SMB services, providing early warnings of potential WantToCry operations.”
  • Bleeping Computer relates,
    • “Threat actors brute-forced VPN credentials and bypassed multi-factor authentication (MFA) on SonicWall Gen6 SSL-VPN appliances to deploy tools used in ransomware attacks.
    • “During the intrusions, the hacker took between 30 and 60 minutes to log in, do network reconnaissance, test credential reuse on internal systems, and log out.
    • “SonicWall warned in a security advisory for CVE-2024-12802 that installing the firmware update alone on Gen6 devices does not fully mitigate the vulnerability, and a manual reconfiguration of the LDAP server is required. Failing to do so leaves open the possibility of bypassing MFA protection.”
  • The American Hospital Association lets us know,
    • “Microsoft announced May 19 that it disrupted operations of Fox Tempest, a threat actor operating as a malware-signing-as-a-service used by cybercriminals to deploy malicious code, including ransomware. Microsoft said Fox Tempest has enabled attacks on a range of sectors in the U.S. and internationally, including health care, education, government and financial services. The actor has been linked to other ransomware groups, including INC, Qilin and Akira. 
    • “One component of modern security is that software packages need to be digitally signed to prove their authenticity,” said Scott Gee, AHA deputy national advisor for cybersecurity and risk. “Normally, these signatures can only be provided by trusted, verified sources. Fox Tempest provided these signatures to malware so that it appeared to be legitimate to security systems. This service enabled a number of ransomware actors to attack health care and other sectors. Microsoft has revoked over 1,000 certificates issued by Fox Tempest. Hospitals and health systems should ensure that certificate verification is enabled on their cybersecurity toolsets.” 
  • and
    • “Cyberattacks against hospitals, health systems and mission-critical health care third-party providers have surged in recent years. While these attacks often involve theft of patient data and medical research, the most concerning are high-impact ransomware attacks that continue to shut down critical medical systems, resulting in disruption and delays to health care delivery. There is no doubt that these types of disruptive attacks create a direct risk to patient and community safety. To be clear, these are not data-theft crimes, they are in fact “threat to life” crimes.
    • “The perpetrators of these foreign-based ransomware attacks are primarily, but not exclusively, Russian-speaking or based in Russia. Other adversarial nations that provide shelter for dangerous international criminals to launch cyberattacks against the U.S. are the usual suspects — Iran, China and North Korea.
    • “There have been thousands of ransomware and data theft attacks targeting U.S. health care over the last several years. In fact, the FBI reported that in 2025 alone, the health care sector suffered 460 ransomware attacks, far more than any other critical infrastructure sector. Since 2020, over 3,200 hacking incidents have been reported to the Department of Health and Human Services Office for Civil Rights, impacting 574 million individuals. Many incidents were actually encryption ransomware attacks accompanied by data theft — “the double extortion,” in which the perpetrators demand an additional ransom for both a decryption key to unlock systems and in exchange for not publishing stolen patient health records.
    • “The silver lining? We have a great deal of “battle experience” and tough lessons learned, which has helped us collaborate to harden systems and prepare for impact and recovery. We at the AHA, working with victims, the field and the federal government, have also been able to reliably identify strategic cyber risk related to third parties, patient safety and supply chain.
    • The top three risks are
      • Geopolitical tensions
      • Cyberattacks agains third parties, and
      • Autonomous Artificial Intelligence-generated and -facilitated Cyberattacks.

From the cybersecurity defenses front,

  • Cyberscooop reports,
    • “On Wednesday [May 20], Microsoft released two new red teaming tools — Rampartand Clarity — meant to help developers design more secure agentic software and assist incident responders in the face of ongoing breaches.
    • “Rampart is built on top of PyRIT, an existing open automation framework Microsoft developed for red teaming generative AI systems. But while PyRIT scans already-built systems for security flaws, Rampart is made to continuously test code for vulnerabilities during the development process, encoding both adversarial and benign testing scenarios into the software development pipeline to flag exploitable bugs and dependencies.
    • “Microsoft said Rampart was built to focus on cross-prompt injection attacks, where “an agent retrieves or processes potentially poisoned content from documents, emails, tickets, and other data sources that manipulate behavior indirectly.” It also confirms fixes or exploits work as intended through multiple rounds of testing, as opposed to tools that perform “single shot validation.”
    • “The second tool, Clarity, can be run as a desktop app, a web interface or directly embedded into a coding agent to provide real time security engineering guidance to developers at the outset of a project. It can categorize and track different business objectives related to the code and highlight downstream security implications along with more secure by design alternatives.”
  • Per Dark Reading,
    • “AI Agents Are Shifting Identity Security Budget Dynamics.”
    • “AI agent projects are proliferating throughout the enterprise, and those AI agent identities require management, security, and governance. New Omdia research shows the AI agent identity budget dynamics are very different than traditional IAM projects.”
  • Per Cyberscoop commentaries,
    • “The Canvas breach proved that prevention is no longer enough.
    • “Cybercriminals brought down the most widely used learning platform in North America. The Canvas breach is a blueprint for how SaaS attacks now work — and a warning about how unprepared most organizations still are.”
  • and
    • “The readiness paradox: Why a false sense of cyber confidence is becoming a liability
    • “As AI expands the attack surface and alert fatigue grows, cyber exposure management offers a clearer path to understanding where risk truly concentrates and how to reduce it before a crisis hits.”
  • Here is a link to Dark Reading’s CISO Corner.

Friday report

Simplificity is a virtue.

From Washington, DC

  • Roll Call reports,
    • “The House Appropriations Committee advanced a draft fiscal 2027 Legislative Branch spending bill on Wednesday that would slash the budget for the Government Accountability Office by nearly one-quarter and give a boost to Capitol Police.
    • “The party-line vote of 34-28 came after a contentious markup stretching late into the evening, as Democrats argued the GAO cut would undermine its mission.”
  • The Hill informs us,
    • “Federal Reserve Chair Kevin Warsh was sworn in Friday beside President Trump, kicking off his term as the new head of the central bank at a critical time for the U.S. economy.” * * *
    • “Warsh, 56, returns to the Fed board after serving as a member from 2006 to 2011. He was nominated to the Fed by former President George W. Bush, whom he served as a White House economic adviser before becoming the youngest Fed board member in history.
    • A graduate of Stanford University and Harvard Law School, Warsh also worked at Morgan Stanley and served in various academic and advisory roles outside of his government service. 
    • Warsh was most recently a fellow at Stanford’s Hoover Institution, an influential conservative think tank known for its close ties to prominent Republican policymakers.
  • Healthcare Dive relates,
    • “The HHS is continuing its crackdown on healthcare fraud, launching a program that will use artificial intelligence to examine audits from states and other federal grant recipients — and potentially affect Medicaid funds.
    • “The Office of the Assistant Secretary for Financial Resources will look across all states to analyze at least five years of audits that grantees file annually with the federal government, the department said Thursday. 
    • “The agency says past audits include internal control issues and “chronic” noncompliance. If recipients aren’t able to fix those problems, the HHS could temporarily withhold payments, hold back future funds, or suspend or terminate awards.”

From the Food and Drug Administration front,

  • The American Hospital Association News reports,
    • “The Food and Drug Administration has issued an early alert for all heart pump controllers by Abiomed, which sent a correction notice to all customers with updated use instructions. The FDA said that Abiomed identified an issue where if a patient is treated with a left ventricular Impella device and experiences an extended period longer than 80 minutes with no residual pulsatility, the Abiomed Automated Impella Controller may be forced to restart due to an internal software error.” 
  • Per an FDA news release,
    • “Today, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis. Bulevirtide is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis (scarring), liver cancer, liver failure, and even death.
    • “Today’s approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available,” said Wendy Carter, D.O., Acting Director of the Office of Infectious Diseases in FDA’s Center for Drug Evaluation and Research. “For individuals living with this chronic viral infection, this new treatment option offers hope in managing a disease that can rapidly progress to serious liver complications.”

From the judicial front,

  • Bloomberg Law reports,
    • “The importance of the $885 million antitrust verdict this week against Takeda Pharmaceuticals Co. Ltd. had less to do with the nine-figure damages than ending private plaintiffs’ losing streak challenging deals delaying cheaper generics.
    • “The Boston federal jury’s finding that Takeda improperly paid a competitor to delay it from bringing a generic version of its Amitiza constipation medication to market marked the first time a private plaintiff won at trial in a reverse-payment case.
    • “Most challenges to deals between branded drug companies and generic makers either settle or are dismissed before reaching trial, with the more nuanced agreements sometimes making it to a jury. Three have been tried before a jury since the US Supreme Court put drugmakers on notice that the dealings could run afoul of antitrust laws. Until Monday, juries had rejected plaintiffs’ claims each time. 
    • “I expect the case to send ripples through legal departments — if not boardrooms — across the country,” said Robin Feldman, a law professor at the University of California in San Francisco who studies pharmaceutical regulation and intellectual property. She called the verdict a “groundbreaking decision.”

From the public health and medical / Rx research front,

  • The Centers for Disease Control and Prevention announced today,
    • “RSV activity started later than usual in most parts of the United States, but illnesses are not more severe than recent years. Activity has peaked in most regions of the country. Because of the later start, some areas of the country may continue to see higher levels of RSV through May. Emergency department visits and hospitalizations for RSV are highest among infants and children less than 4 years old. COVID-19 activity is low in most areas of the country. Seasonal influenza activity is low.”
  • The University of Minnesota’s CIDRAP reports,
    • “As the nation moves closer to topping last year’s measles total in just the first half of 2026, the Centers for Disease Control and Prevention (CDC) today confirmed 59 new cases in a nationwide outbreak that has now reached 1,952 infections. 
    • “All but nine cases are locally acquired, with the rest related to international travel. The total for all of last year was 2,288 confirmed cases.”
  • and
    • “Although an Ebola outbreak is growing rapidly in central Africa, experts say it doesn’t pose a public health threat to the United States.
    • “The outbreak, centered in the Democratic Republic of the Congo (DRC), has grown to nearly 750 suspected cases and more than 170 deaths, the World Health Organization (WHO) announced today. Although the risk from Ebola in the DRC is high, the risk of global spread is low, WHO Director-General Tedros Adhanom Ghebreyesus, PhD, said. 
    • “Many US infectious diseases experts agree.
    • “This is a horrible situation in affected areas of Africa,” said Michael T. Osterholm, PhD, MPH, director of the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, which publishes CIDRAP News. “But for the world, it is not.”
    • “That’s because Ebola, which spreads through contact with bodily fluids, is far more difficult to spread than the airborne respiratory viruses that Americans have confronted in recent years, such as influenza, COVID-19, measles, and even the Andes strain of the hantavirus, which recently caused an outbreak on a cruise ship.”
  • BioPharma Dive points out,
    • “ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting.
    • “Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.”
  • Per a National Institutes of Health news release,
    • “A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events GLP-1 receptor agonists trigger within neurons, which have been largely unexplored until now. A study in mice identified key intracellular signaling processes that are tied to the weight-loss effects of the GLP-1 drug semaglutide. The findings improve our understanding of how increasingly prevalent GLP-1s may influence human behavior and identify new opportunities to potentially enhance treatment.
    • “The weight-loss benefits of GLP-1s are well documented and scientists generally know the brain regions associated with these effects. However, several questions remain, such as why responses to medication differ between patients and why the effects for most eventually plateau.
    • “We know much less about the nuts and bolts of what goes on within the neurons that these medications target. By digging into these mechanisms, we’re beginning to answer some of these questions,” said co-corresponding author Andrew Lutas, Ph.D., an investigator at NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).”
  • CNN reports,
    • “Pregnant women are routinely advised to take prenatal vitamins for their health and their baby’s development. Now, a new study published Monday in JAMA Network Open concluded that children whose mothers received higher-dose vitamin D supplements during pregnancy performed better on certain memory tests at age 10.”
  • MedPage Today relates,
    • “Preserved global brain structure appeared to buffer cognitive decline in people with Alzheimer’s pathology.
    • “Younger-appearing brains had weaker links between pathology and poorer outcomes in multiple cognitive domains.
    • “Other measures of brain reserve or cognitive reserve showed no clear protective cognitive effect.”
  • Health Day tells us,
    • “Middle-aged people who have migraine with an aura could be more at risk for stroke.
    • “Those who had migraine with aura had a 73% increased risk of stroke
    • “Middle-aged men who suffered any kind of migraine had a more than 3.5-fold increased risk of stroke.”
  • and
    • “Use of calcium, vitamin D, or combined supplementation has little to no effect on the prevention of fractures and falls in adults, according to a review published online May 20 in The BMJ.
    • “Olivier Massé, Pharm.D., from CIUSSS du Nord-de-l’Île-de Montréal, and colleagues conducted a systematic review and meta-analysis to examine the effect of calcium, vitamin D, or combined supplementation on fractures and falls in adults. A total of 69 trials, with 153,902 participants, were included in the review.
    • “Most trial participants were community dwelling (87 percent) and not at high fracture or fall risk (73 percent). The researchers found that little to no effect was found from use of calcium supplements (risk ratio, 0.91), vitamin D supplements (risk ratio, 1.00), or combined supplementation (risk ratio, 0.91) for the primary outcome of any fracture. There was little to no effect on other fracture and fall outcomes seen for calcium, vitamin D, or combined supplementation, based mainly on moderate-to-high certainty of evidence. After extensive exploration of heterogeneity across multiple subgroup analyses, the findings remained robust.”
  • BioPharma Dive informs us,
    • “The outlook for an experimental Parkinson’s disease drug dimmed on Thursday with the announcement that it had failed a key clinical trial.
    • “Developed through a partnership Denali Therapeutics and Biogen, the drug is designed to inhibit an enzyme tied to one of the most common genetic drivers of Parkinson’s: a gene called LRRK2. When this gene mutates, it causes the waste disposal systems in cells to malfunction, leading to the buildup of toxic proteins that damage and destroy neurons.
    • “In 2022, Biogen and Denali kicked off what would ultimately become a nearly 650-person trial that pitted their drug against a placebo. The companies are now saying this mid-stage study showed the drug — codenamed BIIB122 — was not significantly better at slowing the disease progression, as measured by a well-known scale clinicians use to assess how Parkinson’s is affecting a patient’s movement and daily life.”

From the U.S. healthcare business and artificial intelligence front,

  • Per an EBRI news release,
    • “The Employee Benefit Research Institute (EBRI)/Greenwald Research Consumer Engagement in Health Care Survey found that the majority of insured individuals still receive health insurance through their employer.
    • “Employment-based health coverage remained the dominant source of health insurance for privately insured adults, with six in 10 receiving coverage through their own job.” * * *
    • “Coverage patterns have been largely stable, with about one-third enrolled in individual-only coverage and most others covering a spouse or partner.”
  • Fierce Pharma relates,
    • “With both Novo Nordisk’s and Eli Lilly’s oral GLP-1s establishing their footing in the U.S. obesity market, the companies’ respective Wegovy pill and orforglipron tablet Foundayo are making their mark on prescription trends for a class previously confined primarily to injectables.
    • “Looking at the past four weeks, total U.S. GLP-1 prescriptions were up 3.6%, compared to 1.8% at the same time last year, analysts at Citi wrote in a Friday note to clients, citing script tracking data from IQVIA. The Citi team attributed that momentum to the ability of Novo’s and Lilly’s new oral launches to “broaden and reshape the market” for obesity incretin drugs.”
  • MedCity News considers whether “Mark Cuban’s Cost Plus Wellness Appeal to Employers?”
    • Employer advocates said Cost Plus Wellness could help spur more direct contracting and transparency in healthcare, though they questioned whether the model can scale and adequately measure provider quality and outcomes.
  • Beckers Hospital Review reports,
    • “Philadelphia-based Penn Medicine reported an operating income of $238.5 million (2.4% margin) for the nine months ended March 31, up 46.3% from $163 million (1.9% margin) in the same period last year, according to financial documents filed May 20.
    • “The results follow the April 1, 2025, acquisition of Doylestown (Pa.) Health. Doylestown Hospital, a 245-bed teaching hospital, became Penn Medicine’s seventh hospital and is now known as Penn Medicine Doylestown Health.”
  • STAT News tells us,
    • “Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday. 
    • “Retro has a big mission: Add 10 healthy years to the human lifespan. It is seeking to do that by using a variety of technologies, including in vivo gene therapies, cell replacement therapies, and other approaches to spur younger, healthier cells into aging tissues.
    • “The company is currently running its first clinical trial — testing a pill designed to enhance the body’s ability to better clear out protein aggregates in patients with Alzheimer’s disease. Retro CEO Joe Betts-LaCroix told the audience at STAT’s Breakthrough Summit West on Tuesday that the trial is going “super good” and that researchers haven’t seen any dose-limiting toxicities. He said he anticipates releasing some data from the trial around August.”  
  • Fierce Healthcare informs us,
    • “Innovaccer acquired CaduceusHealth to combine its AI platform with the company’s revenue cycle management services and staff to serve ambulatory care providers.
    • ‘Innovaccer, founded in 2014, built software solutions to unify enterprise data and applies AI to automate manual tasks and streamline workflows for payers and providers. Last year, it rolled out Flow Auth, an AI-powered prior authorization solution that is part of Flow by Innovaccer, an AI-powered revenue cycle suite designed to modernize financial operations for health systems. Other capabilities include Flow Capture, an autonomous medical coding solution and Flow Collect, an AI-powered denial management and revenue recovery tool.
    • “Innovaccer claims that it now serves over 200 health systems and payers, 95% of community pharmacies and 80 million patient lives across the United States. Flow is built on Gravity, Innovaccer’s healthcare AI infrastructure platform.”
  • and
    • “Eugene, Ore.-based Ksana Health is undertaking a multi-institutional research effort aimed at creating a new class of artificial intelligence to advance mental health and substance use disorder treatment and prevention.
    • “The software company was awarded a $17.9 million contract by the U.S. Department of Health and Human Services (HHS) to create a Large Health Behavior Model (LHBM). Its goal is to train AI models on smartphones and other wearables data, including sleep, mobility and language use linked to large scale electronic health records (EHRs).
    • “This initiative augments Ksana’s current efforts to shift behavioral healthcare from episodic, subjective assessment toward continuous, data-driven health promotion, reducing healthcare spending, improving quality of life, and reaching populations that currently lack access to effective behavioral health support,” said Tony Scripa, Ksana Health COO and project co-investigator, in a statement.”
  • and
    • “More than seven in 10 Medicare members report feeling confusion or uncertainty when navigating online health information, a new whitepaper from CVS Health found. 
    • “The research (PDF) drew insights from Medicare-eligible consumers through surveys, interviews and ethnographic studies. 
    • “Seventy-one percent of respondents report an eagerness to use more digital health care tools and 86% report an eagerness to use them. However, 58% of respondents report that low digital health literacy is negatively impacting their ability to manage their health. 
    • “We’re caring for the fastest-growing and most clinically complex population in the country, and what we found in the research challenges a common assumption—older adults actually are more open to engaging with technology than many think,” said Dr. Benjamin Kornitzer, M.D., Aetna senior vice president and CMO, in a statement. “It creates a real opportunity to meet them where they are and provide day-to-day support, whether it’s managing medications, following up after a visit, or staying on track with chronic conditions. Technology and engagement can help them live healthier, more independent lives.”
    • “As a result, CVS said it is applying insights from the research across its digital offerings, including clearer navigation, stronger accessibility features and added privacy and security transparency.” 

Thursday report

Simplicity is a virtue.

A commenter, Patrick Morselli, accurately observed in response to the OPM Director’s blog post that “Simplicity has a high cost in most organizations. Feels like the hardest work is undoing complexity other smart people left behind.”

From Washington, DC

  • The Wall Street Journal reports,
    • “Senate Republicans broke with President Trump over his administration’s plan to create a $1.8 billion settlement fund to pay people who claim political persecution, with widespread opposition forcing party leaders Thursday to abandon votes on immigration-enforcement funding and send lawmakers home early for their Memorial Day break.
    • “The “anti-weaponization” fund is a Trump priority, after he alleged for years that his supporters, including those prosecuted over the Jan. 6, 2021, attack at the Capitol, had been targeted unfairly by the Biden administration. But its creation has run into blowback in the Senate, and the immigration-enforcement bill gave senators leverage to dig in their heels.
    • “I don’t like the fund at all,” said Sen. John Curtis (R., Utah), who added he didn’t think any guardrails could fix it. Sen. Thom Tillis (R., N.C.), a frequent target of Trump criticism who is retiring, called it a “payout pot for punks.”
    • “With no resolution in sight, Senate Majority Leader John Thune (R., S.D.) sent senators home for their weeklong Memorial Day recess, putting the Republican-led Congress on course to miss Trump’s deadline to have the Immigration and Customs Enforcement and Border Patrol measure on his desk by June 1.”
  • Healthcare Dive relates,
    • “Lawmakers are mulling reform of how Medicare pays physicians, concerned that insufficient reimbursement in the federal insurance program is incentivizing consolidation and increasing healthcare costs.
    • “Physician pay has declined over the past two decades when accounting for inflation, spurring independent providers to be acquired by hospital systems rather than go it alone, provider witnesses told representatives during a House Energy and Commerce subcommittee hearing Wednesday. And representatives agreed that’s a concern.
    • “Making sure that independent physician practices stay open […] is one of the most critical ways we can ensure competition and drive down costs,” said Rep. Kim Schrier, D-Wash.”
  • The American Hospital Association adds,
    • “Rep. Randy Feenstra, R-Iowa, introduced the Rural Maternity Options for Medical Support Act on May 19. The bill would guarantee that beds used solely for labor and delivery are not counted toward the 25-bed limit for critical access hospitals. The bill is co-sponsored by Reps. Darin LaHood, R-Ill., Jill Tokuda, D-Hawaii, and Kim Schrier, D-Wash. 
    • “New and expecting moms deserve access to high-quality labor and delivery services,” said Lisa Kidder Hrobsky, AHA senior vice president for advocacy and political affairs. “The Rural Maternity Options for Medical Support Act of 2026 strengthens access to maternal health services for mothers in rural areas by ensuring that higher volume critical access hospitals have labor and delivery beds available, even if their other patient beds are full. The AHA appreciates Rep. Feenstra’s leadership to support critical access hospitals and families across the nation.” 
  • and
    • “The House Education and Workforce Committee May 21 unanimously passed the Transparency in Billing Act (H.R. 8684). The bill would require off-campus hospital outpatient departments to obtain a separate unique health identifier and include it on all claims for services billed to commercial group health plans or their enrollees. The legislation would prohibit the health plan from paying the claim and the hospital from collecting payment from the plan enrollee if the claim excludes the identifier, and it would impose civil monetary penalties on hospitals that violate the requirement. 
    • The AHA has previously opposed this policy, saying that hospitals are already transparent about the location of care delivery on their bills and that it would create a significant administrative burden to providers and the health care industry at large.” 
  • Fierce Healthcare tells us,
    • “Health and Human Services Secretary Robert F. Kennedy Jr. removed two key leaders of the U.S. Preventive Services Task Force (USPSTF), a key advisory panel that offers guidance on preventive services, according to media reports.
    • ‘Vice chairs John Wong, M.D. and Esa Davis, M.D. were dismissed from the task force in letters sent to them by Kennedy on May 11, The New York Times reported on Wednesday, citing copies of the letters obtained by reporters. STAT, CNN, Politico and The Hill also reported the terminations, citing the letters.” * * *
    • “The terminations leave the panel with just eight sitting members. Five other members saw their terms expire at the start of this year, and Kennedy did not replace them, and the previous chair, Michael Silverstein, departed on his own, STAT reported.”
  • Federal Network News informs us,
    • “Shane Stevens, the top official for the Office of Personnel Management’s healthcare and insurance arm, is stepping down from his role, Federal News Network has learned.
    • “Stevens, a political appointee, has been serving as associate director of healthcare and insurance at OPM since last summer. He announced in an email Thursday afternoon that he is voluntarily resigning, effective immediately.”
  • Best wishes, Mr. Stevens. Thanks for your service.
  • Tammy Flanagan, writing in Govexec, lets us know “what federal employees get wrong about divorce and retirement.”
    • “Errors involving survivor benefits, health coverage and court orders can create financial problems years after a marriage ends.”
  • FedWeek explains “Insuring Children at College and Federal Benefits Considerations (with a Checklist).”

From the Food and Drug Administration front,

  • Radiology Business reports,
    • “Medtronic is recalling more than 18,000 surgical devices due to a risk of contamination. The recall includes certain lots of the company’s Gundry and DLP retrograde cannulae, which are cardiopulmonary bypass vascular catheters used to perform open heart surgeries.
    • “This recall was put in place due to the potential of a sterile barrier breach. Only certain lots of these devices are included in the recall.
    • ‘The U.S. Food and Drug Administration (FDA) has ruled this as a Class II recall. This means the agency believes these devices could cause “temporary or medically reversible adverse health consequences.”
  • STAT News relates,
    • “Wearable maker Whoop has not resolved a dispute with the Food and Drug Administration over a blood pressure feature the company launched last year, according to a top health executive at the company. 
    • “FDA warned Whoop last July over the feature that gives users a daily estimate of their systolic and diastolic blood pressure, saying that it’s a medical device that requires agency review. Whoop argues that the feature is exempt from FDA review because it is intended for wellness purposes.” * * *
    • “The dispute between FDA and Whoop turned up the heat in a simmering debate about how the agency ought to oversee low-risk products. Proponents of deregulation argue that the time and expense required for FDA authorization impede innovation and that FDA review is unnecessary to ensure the safety of many products that potentially benefit consumers.”

From the judicial front,

  • Federal News Network reports,
    • “Some federal employees may now have an easier time qualifying for disability retirement benefits, following a recent precedential decision from the U.S. Court of Appeals for the Federal Circuit.”
    • “In April, the court ruled that federal employees’ disability retirement applications cannot be denied solely based on a lack of “objective” medical evidence. The ruling applies in cases where federal employees have already been removed from their jobs due to a “medical inability to perform.”
    • “Objective documentation, like lab tests or prescription lists, can support an argument but cannot be the sole basis for denying claims, the court said. “Subjective” medical evidence, like a diagnosis based on self-described symptoms, must also be considered. If employees’ disability retirement claims rely on subjective evidence, they won’t automatically be denied benefits.
    • “The decision last month overturned a 2024 ruling from the Merit Systems Protection Board, which had upheld the Office of Personnel Management’s denial of a disability retirement application from a former OPM employee in 2016.”
  • The New York Times relates,
    • “The Justice Department announced charges on Thursday against 15 people for attempting to defraud Minnesota Medicaid and other social service programs in the state of more than $90 million. 
    • “Top officials, including Robert F. Kennedy Jr., the health and human services secretary, and Mehmet Oz, head of the Centers for Medicare and Medicaid Services, appeared in Minneapolis to announce the charges. “The fraud here in Minnesota is shocking,” said Colin McDonald, an assistant attorney general overseeing the administration’s crackdown on fraud.
    • “Among the defendants are an owner and an employee of autism clinics, who are charged with submitting $46.6 million in fraudulent claims to Medicaid, the public health plan that covers low-income people. Additional defendants were charged with filing bogus claims to Medicaid for other services, including those that assist disabled people with obtaining housing and living independently.”

From the public health and medical / Rx research front,

  • The Wall Street Journal reports,
    • “The world’s most popular weight-loss and diabetes drugs are linked to a powerful new possible benefit: better outcomes for cancer patients. 
    • “A suite of four new studies suggest that people taking so-called GLP-1 drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro saw reductions in tumor progression, lower overall chance of death and less risk of developing breast cancer.
    • “It’s really provocative that they showed, in several cancers, that people who took these drugs seem to have a lower risk of their cancer returning,” said Dr. Jennifer Ligibel, a breast oncologist at the Dana-Farber Cancer Institute who wasn’t involved in any of the studies.
    • “One study from researchers at the Cleveland Clinic Cancer Institute tracked more than 10,000 patients with early-stage cancers who started GLP-1 drugs after diagnosis and compared their disease progression to those on a different diabetes medication. Those on GLP-1s were less likely to see their cancer spread.
    • “In lung cancer patients, the rate of progression to advanced disease was cut roughly in half—10% in GLP-1 users versus 22% in the comparison group. Breast cancer patients showed a similar pattern, with progression rates of 10% versus 20%. Colorectal and liver cancers also showed statistically significant reductions.”
  • and
    • “An investigational drug developed by Eli Lilly LLY  delivered clinically meaningful weight loss in a trial, the company said as it looks to expand its obesity treatment portfolio amid soaring demand.
    • “Lilly said Thursday that retatrutide, designed to be taken once a week, met the primary endpoint in a phase 3 clinical trial, as well as key secondary endpoints.
    • “According to Ania Jastreboff, a Yale School of Medicine professor and lead investigator for the trial, every dose of retatrutide assessed resulted in clinically meaningful weight reduction for nearly all participants. On average, those with severe obesity on the highest dose lost 30% of their body weight over two years, Jastreboff added.
    • “The trial evaluated the therapy’s efficacy and safety on adults who are overweight and had other medical conditions such as type 2 diabetes, chronic pain and cardiovascular issues.
    • “More results will be shared later this year, Lilly added.”
  • Healio adds,
    • “Studies show that GLP-1 receptor agonists have significant potential for treating glaucoma, diabetic retinopathy and other eye diseases, but important nuances remain to be investigated, according to a review published in BMC Ophthalmology.
    • “Although GLP-1 RAs have revolutionized metabolic disease management, their potential therapeutic role in ocular diseases — particularly those driven by shared metabolic and inflammatory pathways — remains underexplored,” Yu Luo, of Beijing University of Chinese Medicine, and colleagues wrote. “Their multifaceted neuroprotective properties and anti-inflammatory mechanisms present a distinctive therapeutic opportunity for ophthalmic pathologies, potentially offering direct ocular benefits beyond systemic metabolic control.”
  • and
    • “Adults with obesity achieved greater long-term weight loss if they partook in a nutrition plan designed for rapid weight loss compared with one designed for gradual weight loss, according to trial data.
    • “Line Kristin Johnson, RD, PhD, senior researcher at Vestfold Hospital Trust in Norway, said there has been debate among researchers regarding whether rapid weight loss leads to worse long-term outcomes for people with obesity. In findings from a randomized pragmatic trial presented at the European Congress on Obesity, Johnson and colleagues found implementing a calorie-restricted eating pattern for rapid weight loss can induce a larger decrease in body weight at 1 year than a gradual weight-loss eating pattern.”
  • Endocrinology Advisor points out,
    • “Life-course body size progression, particularly transitioning from a thinner childhood body size to adult obesity, significantly increases risks for stroke, coronary artery disease, and heart failure.”
  • Healio also notes,
    • “Only a third of cancer survivors receive advice on weight control and improving their diet from health care professionals, and less than half are informed about the benefits of physical activity.
    • “Individuals who do receive advice on losing weight, salt and fat intake, and exercise are three to eight times more likely to engage in healthy behaviors than those who did not.
    • “We need more effort to deliver lifestyle behaviors to patients,” Chao Cao, PhD, MPH, instructor in the department of medical oncology at Dana-Farber Cancer Institute, told Healio.”
  • Fierce Pharma tells us,
    • “Phase 3 data for Merck & Co. and Kelun-Biotech’s antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) suggest the race is heating up to establish a new standard of care in first-line non-small cell lung cancer.
    • “According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with Keytruda slashed the risk of disease progression or death by a major 65% compared with Keytruda alone in treatment-naïve, PD-L1-positive NSCLC. The p-value is below 0.0001, suggesting high statistical significance.
    • “Key overall survival results, which will underpin regulatory considerations in first-line NSCLC, were not mature at the Sept. 29, 2025, data cutoff, but a strong trend with a preliminary 45% improvement in favor of the combo arm was observed.” 
  • Per MedPage Today,
    • “Undetected attention deficit-hyperactivity disorder (ADHD) was not uncommon among adults hospitalized after traffic accidents, according to a cross-sectional study from the Dominican Republic.
    • ‘Among 95 adults admitted for traffic-related injuries without a prior diagnosis, more than a third (34.7%) screened positive on the Adult ADHD Self-Report Scale, reported Amanda Abreu, MD, of the Universidad Iberoamericana in Santo Domingo, Dominican Republic.
    • “High-risk driving behaviors — including violations, mistakes, and slips — were more common among adults who screened positive (66.6% vs 30.6%, P=0.0016), she reported at the American Psychiatric Association annual meeting.
    • “We’re not saying that ADHD alone caused the accidents, nor are they unsafe drivers, but these findings suggest that this is a really vulnerable population we should look into, and we should help protect,” Abreu said.”
  • and
    • “Low-risk pancreatic cystic lesions were found to be associated with a long-term risk of pancreatic cancer in a retrospective cohort study.
    • “The incidence rate of pancreatic cancer among patients with pancreatic cystic lesions was higher than that of the general population (1.89 vs 0.14 per 1,000 person-years).
    • ‘Over a quarter of patients were diagnosed with pancreatic cancer more than 5 years after detection of lesions, suggesting longer-term follow-up is needed to avoid missed diagnoses.”
  • Per the Wall Street Journal,
    • “New French research links natural food color additives to increased risks of Type 2 diabetes and cancer, similar to synthetic dyes.
    • “Beta-carotene, curcumin and anthocyanins used as color additives were linked to a higher risk of Type 2 diabetes. Beta-carotene used as a food coloring was also linked to breast cancer.
    • “The findings challenge the Trump administration’s push for natural dyes and food companies’ shift away from artificial colors.”
  • Per BioPharma Dive,
    • “BioMarin is looking to expand the use of its top-selling medicine, Voxzogo, with positive study results released Wednesday.
    • I’n 2021, Voxzogo became the first drug approved to improve growth in children with achondroplasia, the most common form of dwarfism. The new results pertain to a related condition called hypochondroplasia that generally presents in less severe ways and might not be noticed until later in a child’s life.
    • ‘In the Phase 3 trial, researchers found participants given Voxzogo were growing faster than those who received a placebo. After a year, the Voxzogo patients also had significant increases in standing height and arm span, a key finding that could help children function better in daily tasks and retain more independence.”

From the U.S. healthcare business and artificial intelligence front,

  • Managed Healthcare Executive reports,
    • ‘For the average person, healthcare costs rose 7.9% in 2026 to $8,460, which is the highest annual increase in more than a decade, according to the 2026 Milliman Medical Index
      (MMI). For a hypothetical family of four, healthcare costs reached $37,824, Milliman found. The Milliman Medical Index measures healthcare costs covered by a typical employer-sponsored health insurance plan.”
    • “The increase reflects structural forces that are not going away, Milliman Principal and Consulting Actuary Deana Bell said in a news release. “Outpatient costs have quadrupled for the MMI’s family of four since the MMI was first published in 2005, with much of the trend exacerbated by delivery system consolidation, specialty drug growth, and site-of-care shifts.”
  • Beckers Hospital Review relates,
    • “The National Council of State Boards of Nursing found the District of Columbia has the most licensed nurses per capita, while Utah is the state with the fewest for the second year in a row.
    • “The organization created a course of nursing licensure statistics in the U.S. and its territories. The data was compiled using the NCSBN’s database and Nursys, an electronic information system where regulatory bodies enter licensure data. All of the council’s 58 members shared licensure data, which amounted to 6,903,665 registered and practical nurses — up from 6,870,362 last year.
    • ‘According to the data, Wyoming and Vermont had the fewest licensed nurses in their states overall, at 9,620 and 13,528, respectively. Meanwhile, California and New York had the most licensed nurses at 708,141 and 610,207, respectively.” 
  • Healthcare Dive tells us,
    • “Nonprofit health system Providence is throwing in the towel on the majority of its health insurance businesses, citing the difficulty of running a regional health plan amid regulatory pressures and rising costs.
    • “Starting next year, Providence, which covers about 440,000 people in a handful of western states, will no longer offer Medicaid, Affordable Care Act or employer-sponsored plans, the Renton, Washington-based system announced on Wednesday.
    • ‘The decision comes as Providence attempts to shore up its financial footing and refocus on delivering care. Still, the company plans to maintain its Medicare Advantage operations through a partnership with a national carrier, according to the release.”
  • Modern Healthcare tells us,
    • “Sutter Health and Allina Health have moved a step closer to joining forces.
    • “Sacramento, California-based Sutter and Minneapolis-based Allina said Thursday they signed a definitive agreement to form a $26 billion combined system with 39 hospitals. The agreement follows a letter of intent announced in March. The proposal is on track to close by the end of the year pending customary regulatory approval, the organizations said in a news release.” 
  • BioPharma Dive informs us,
    • “Eli Lilly has snagged Engage Biologics, a biotechnology company that aims to deliver genetic medicines without viral payloads, in a deal worth up to $202 million.
    • “Lilly said Wednesday it has acquired the preclinical biotech in an all-cash deal, including an undisclosed upfront payment, with the possibility of future payouts based on research, development and commercialization milestones. The acquisition gives Lilly non-viral DNA delivery technology, dubbed the “Tethosome” platform.
    • “We believe that the combination of Engage’s platform with Lilly’s significant capabilities will meaningfully accelerate development of new genetic therapies,” Will Olsen, co-founder and CEO of Engage, said in a statement.”
  • Fierce Healthcare lets us know,
    • “Electronic medical record (EMR) company Canvas Medical launched Canvas Studio Thursday, a no-code interface that allows clinicians and other healthcare professionals to build custom EMR workflows.
    • “Canvas Medical CEO Adam Farren told Fierce Healthcare the company was “serving a market” for software developers to customize workflows for end users within its ONC-certified EHR platform. 
    • “What Studio does is replace the developer with an AI agent, so that the end user, the clinician or administrative staff user, can directly customize and extend Canvas themselves using the agent,” Farren said.”
  • and
    • “Employers are set to significantly increase their use of AI in health benefits, a new survey shows, even as they continue to face barriers to rolling out the tech.
    • “WTW polled 312 employers with about 4.6 million workers for the 2026 AI Use in Health and Benefits Survey, and found that 72% of those surveyed plan to embed AI into their benefits programs in the next two years. By comparison, only 20% said they are currently doing so.
    • “The employers cited several key areas where they see AI likely supporting benefits at work, such as improved communication, cited by 68%, and data insights and analytics, noted by 59%. In addition, 57% of those surveyed said AI would likely support greater personalization.
    • “Jeff Chandler, North America commercialization leader for Health & Benefits at WTW, said in a press release that these top priorities are all “areas where AI can materially improve how benefits teams make decisions and support employees.”

Midweek update

Simplicity is a virtue.

Medium adds, “Simplicity, though not traditionally viewed as a virtue, is the greatest virtue of all because it makes practicing every other virtue that much easier.”

From Washington, DC,

  • Healthcare Dive reports,
    • “Senate Democrats are trying to roll back a pilot program that adds artificial intelligence-backed prior authorization for some services in Medicare. 
    • “Sens. Ron Wyden, D-Ore., Maria Cantwell, D-Wash., Richard Blumenthal, D-Conn., and Kirsten Gillibrand, D-N.Y., introduced a resolution Wednesday that would invoke the Congressional Review Act — a legislative tool lawmakers can use to overturn agency actions — to end the WISeR model, which went into effect in six states this year. 
    • “Democrats have railed against the pilot for months, arguing the model delays or denies Medicare beneficiaries’ care. “Americans are sick and tired of abusive prior authorization tactics putting needed health care out of reach,” Wyden said in a statement. “The last thing seniors need is even more AI denying the care they need.”
  • The American Hospital Association relates,
    • “The AHA May 20 provided comments to the House Energy and Commerce Subcommittee on Health for a hearing on the physician fee schedule, the Medicare Access and CHIP Reauthorization Act and potential payment reform. The AHA highlighted responses to previous congressional requests for information on reform to MACRA and physician payments. They include asking Congress to provide conversion factor updates for the physician fee schedule that reflect changes in input costs and inflation, and to improve cost measures used in the Merit-based Incentive Payment System. The AHA also outlined policy considerations for alternative payment model design, advanced APM participation incentives and accountable care organizations.” 
  • STAT News tells us,
    • “Health secretary Robert F. Kennedy Jr. has elevated a senior health official to serve as an interim surgeon general until that position is filled by a Senate-confirmed nominee. 
    • “Stephanie Haridopolos, a family medicine physician who is currently a senior adviser and chief of staff for the Office of the U.S. Surgeon General, is now the office’s director of health communications, Kennedy told staff in an email sent late Tuesday. According to that email, Assistant Secretary for Health Brian Christine used his “delegation of authority powers” to allow Haridopolos to carry out the duties of surgeon general. 
    • “She will “promote [U.S. Surgeon General] public health actions, advisories, and guidance until our next Surgeon General is sworn into office,” Kennedy said.”
  • An HHS news release adds,
    • “The U.S. Department of Health and Human Services (HHS) Office of the Surgeon General today released the Surgeon General’s Warning on the Harms of Screen Use: An Advisory and Toolkit on How to Protect Children and Adolescents, which raises national awareness about the growing risks associated with excessive and harmful screen use among young people.
    • “Children and adolescents now spend as much or more time on screens as they do sleeping or in school. National estimates show that adolescents average seven to nine hours a day on entertainment screens, and most report using their devices right before bed. What they encounter online and the excessive, and sometimes compulsive, use of screens is increasingly linked to real-world harm.” * * *
    • The Surgeon General’s Warning on the Harms of Screen Use: An Advisory and Toolkit on How to Protect Children and Adolescents is available at https://www.surgeongeneral.gov. Additional resources for families, schools, and communities are available here.
  • Govexec informs us,
    • “Federal employee morale dropped last year, as President Donald Trump downsized and otherwise overhauled the civil service, according to a new data analysis from Gallup. 
    • “[A]fter the reforms took effect, federal workers experienced declines in employee engagement and job satisfaction, alongside increases in burnout and job-search activity,” the researchers wrote. “These shifts were larger than those observed among comparable state and local government workers — and private sector counterparts — during the same period.”
    • “The analytics firm noted, however, that the data shows there was a “rebound” in some areas by the end of 2025.” 
  • Per a Centers for Medicare and Medicaid Services news release,
    • “The Centers for Medicare & Medicaid Services (CMS) proposed today a sweeping crackdown on state Medicaid payment practices that have driven payment rates well above Medicare levels, leading to excessive federal costs. The Medicaid Managed Care State Directed Payments (SDP) and Medicaid Fee-for-Service (FFS) Targeted Practitioner Payments Proposed Rule would set clear caps and better align Medicaid payments with Medicare standards. If finalized, the proposed rule would generate an estimated $775 billion in total savings over 10 years, including $510 billion in federal savings. Our goal: to refocus Medicaid dollars on individuals and families instead of inefficient payment schemes.
    • “The proposed rule would:
      • “Cap SDP provider payment rates at 100% of Medicare payment rates for expansion states and 110% of Medicare payment rates for non-expansion states (or 100% of the Medicaid state plan rate if a comparable Medicare rate is not available), consistent with section 71116 of the WFTC legislation and historical Medicaid FFS payment levels,
      • “Apply similar limits to certain targeted Medicaid fee-for-service payments, and
      • ‘Establish consistent national standards to improve transparency and accountability.
    • “CMS is seeking public comment on the proposed rule, including feedback on implementation. “To view the proposed rule on the Federal Register, visit: https://www.federalregister.gov/d/2026-10292. 
    • “To view the fact sheet, visit: https://www.cms.gov/newsroom/fact-sheets/medicaid-managed-care-state-directed-payments-medicaid-fee-service-targeted-medicaid-practitioner“

From the Food and Drug Administration front,

  • BioSpace reports,
    • “No child deaths were directly linked to COVID-19 vaccines, according to the FDA’s long-awaited analysis of adverse events.
    • “Late last year, former CBER director Vinay Prasad claimed in a leaked internal memo that “at least 10 children have died after and because of receiving COVID-19 vaccination.” The FDA, after much blowback from the industry and independent experts, promised to disclose its analysis by the end of 2025, but the agency largely kept its specific findings under wraps.
    • “Those findings were made publicly available last week as part of a letter from Sen. Ron Johnson (R-WI) to health secretary Robert F. Kennedy, Jr., seeking for greater transparency around the safety of COVID-19 vaccines.”
  • Fierce Pharma relates,
    • “Patrick Soon-Shiong’s ImmunityBio has convinced the FDA to weigh its case for a potential expansion of its bladder cancer med Anktiva, citing “overlapping features” in the indication it’s targeting with the interleukin-15 agonist’s existing approval. 
    • “The FDA has now accepted ImmunityBio’s application for Anktiva plus the Bacillus Calmette-Guérin (BCG) vaccine in patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ (CIS). The FDA has set a target decision date of Jan. 6, 2027, ImmunityBio said in a May 19 release.” 

From the public health and medical / Rx research front,

  • The American Hospital Association News reports,
    • “The Centers for Disease Control and Prevention yesterday issued an advisory on the Ebola disease outbreak in the Democratic Republic of the Congo and Uganda. The agency said the risk of spread to the U.S. is currently considered low. The notice includes recommendations for clinicians and guidance for U.S. travelers visiting DRC or Uganda. The World Health Organization declared a public health emergency of international concern May 17 due to the outbreak.” 
  • The Washington Post relates,
    • “Teens averaged over 50 minutes of smartphone use between the hours of 10 p.m. and 6 a.m. on school nights, researchers found, and nearly half of the teens used their phones between midnight and 4 a.m. The majority of that phone use was spent on social media apps like YouTube, Instagram or TikTok, the study found. Others were looking at streaming apps or playing games like Roblox or Clash Royale.
    • “The study, published Monday in the journal JAMA Pediatrics, followed the screen use of 657 adolescents, a cohort with an average age of 15. All are participants in the national Adolescent Brain Cognitive Development Study, which includes a racially and economically diverse sample of children and is the largest long-term study of brain development and child health in the United States. 
    • “Researchers drew data from an app installed on the teens’ phones that passively tracked their screen use patterns, said Jason Nagata, the lead author and an associate professor of pediatrics at the University of California at San Francisco. This is significant because “a lot of prior studies have relied on self-reporting of screen use,” he said, which isn’t as thorough or accurate.” * * *
    • “And the full impact on sleep likely goes beyond the minutes spent staring at a glowing screen, Nagata adds. Social media use in particular “is very emotionally activating,” he says. “There’s a lot of stimulation, and that can make it harder for teens in particular to wind down, even after you’ve turned the phone off.”
  • Genetic Engineering and BioTechnology News tells us,
    • “Researchers headed by a team at Icahn School of Medicine at Mount Sinai have discovered that many gut bacteria use a flexible survival strategy—known as epigenetic “bet-hedging”—to withstand disruptions such as antibiotics and diet changes.
    • “Studying infant and gut microbiomes, the investigators showed that microbes can switch between functional states, rather than relying solely on genetic mutations, to try to survive shifting conditions. While bet-hedging has been observed in disease-causing bacteria, this is the first study to show that it is widespread among the beneficial microbes that make up the healthy human gut.
    • “The findings shed light on a previously hidden layer of microbiome biology and may help explain why probiotics and fecal microbiota transplantation (FMT) produce inconsistent benefits across individuals.
    • “Gang Fang, PhD, professor of genetics and genomic sciences and director of the Center for Genomic AI and Microbiome Medicine at the Icahn School of Medicine at Mount Sinai, is senior and corresponding author of the team’s published paper in Cell Host & Microbe, titled “Epigenetic phase variation in the gut microbiome enhances bacterial adaptation
  • STAT News adds,
    • “While Tippi MacKenzie was a postdoctoral fellow in the early 2000s, she and her lab mates experimented with using the then-new technology of gene replacement therapy to try to treat inherited disorders in mice before they were born. Over and over it worked. They cured mice with hemophilia and mice with tyrosinemia. And the whole time, people kept telling her that gene therapy in human fetuses was just around the corner, just five years away. 
    • “It’s now been 25 years, and such a reality has yet to materialize. But after promising discussions with the Food and Drug Administration, MacKenzie is now closer than anyone’s ever been.
    • “Her team has submitted an investigational new drug (IND) application to the agency seeking approval for a small trial that aims to treat five fetal patients with a rare lysosomal storage disorder. The agency told them they could bypass animal testing, because the safety profile of the vector they plan to use already has been so well characterized by other academics and companies developing gene therapies for kids and adults.
    • “Thinking back on it, of course, you can’t really do in utero gene therapy until the field of adult and pediatric gene therapy has been well established,” MacKenzie said Tuesday at STAT’s Breakthrough Summit West. “So we basically had to wait for everything to catch up.”
  • Per a National Institute of Standards and Technology news release,
    • “My Research Is Working Toward a Pain-Free Mammogram Alternative.”\
      • “A woman in the U.S. has a one in eight chance of developing breast cancer. That’s a scary number, but the good news is that more women are being diagnosed early and surviving than ever before. 
      • “We have a long way to go before low-field MRI becomes a common alternative to mammograms. But my fellow researchers and I will continue to work to make this happen, because all patients deserve a highly accurate and pain-free approach to screening for breast cancer.” 
  • Medscape informs us,
    • “Digital tools can enhance GLP-1 therapy for obesity and diabetes by bridging gaps in patient education and follow-up. However, clinicians must focus on meaningful outcomes and personalized guidance to ensure effective use and adherence.”
  • MedPage Today points out,
    • “Antibiotics are sometimes prescribed for lower back pain when more conventional therapies don’t work, based on some studies showing bacteria in affected spinal discs.
    • “In this randomized trial, no benefit from amoxicillin-clavulanate could be discerned for patients with refractory low back pain and herniated discs at 1 year.
    • “The authors recommended that antibiotics no longer be prescribed for this indication.”
  • Per Healio,
    • “Data collected from a number of clinical trials found that despite recent “buzz,” there is no significant link between GLP-1 receptor agonists and the progression of diabetic retinopathy, according to a speaker.
    • “These medications have been labeled not to be good for patients who have preexisting diabetic retinopathy, but I don’t think that is fair,” Majda Hadziahmetovic, MD, associate professor of ophthalmology at Duke University, said during a virtual presentation at Real World Ophthalmology.“Those conclusions actually came from two main clinical trials, and both of those clinical trials were cardiovascular outcome trials. Diabetic retinopathy and retinal health were just the side effects that they were not looking at very carefully.”
  • and
    • “Self-collection may be as effective as clinician-collected HPV tests and improve screening rates.
    • “But its implementation requires OB/GYNs to first transition [from pap smears] to primary high-risk HPV screening.”
  • Infectious Disease Advisor adds,
    • “Screening recommendations for HCV [hepatitis C] have expanded in recent years to include universal screening among adults, with an emphasis on reflexive testing strategies in which a positive HCV antibody (Ab) result automatically triggers confirmatory RNA testing. This approach is intended to reduce delays in diagnosis and improve identification of patients eligible for treatment. To evaluate how these recommendations have influenced testing practices, researchers conducted a retrospective analysis of HCV testing patterns from 2018 to 2024 within a large US commercial laboratory network.” * * *
    • “Increased adoption of reflexive HCV testing, alongside laboratory stewardship initiatives and updated screening recommendations, has contributed to more complete and timely diagnostic evaluation of HCV infection.”
  • Per MedTech Dive,
    • “Medtronic on Wednesday said two analyses of its Symplicity Spyral renal denervation system, presented as abstracts at the EuroPCR meeting in Paris, showed the procedure significantly reduced blood pressure in patients over three years.
    • “Outcomes after renal denervation for 787 patients who had prior cardiovascular events were evaluated in one study, while the second followed 903 people with severe hypertension.
    • “The analyses, from the global SYMPLICITY registry, add to a growing body of evidence supporting renal denervation, Medtronic said.”

From the U.S. healthcare business and artificial intelligence front,

  • 401k Specialist reports,
    • “While some workers believe they’ll be employed past retirement age, the truth is that some may be forced into an early retirement.  
    • “Findings from the 2026 Annual Retirement Study from the Allianz Center for the Future of Retirement show that over half of Americans (53%) currently have a target age they plan to retire at.
    • “However, the reality is that many depart the workforce earlier than initially expected. While the findings report that 53% of Americans retired on their own schedule, 42% had to retire earlier than planned. In fact, only 5% of retirees surveyed reported leaving their role later than anticipated.
    • “The findings emulate recent research from the Society of Actuaries, which showed that 59% of its respondents retired earlier, and only 6% left the workforce later than planned.
    • “When asked why they exited the workforce earlier, Allianz found that most reasons were beyond the retiree’s control. Common causes included health issues that prevented job performance (30%) and unexpected job loss (21%), while others realized they were financially ready earlier than expected (21%).
    • “Finances, as expected, play a major role when deciding when to retire. Retirees must consider day-to-day costs and inflation numbers, along with necessary expenses like medical expenditures as they age.
  • Fierce Healthcare relates,
    • “Patient collections are playing a bigger and bigger role in health systems’ total revenues, bringing a new focus on the difficulties organizations face in securing timely, or any, payments for their services, a new survey report warns. 
    • ‘The poll of 205 healthcare revenue heads, conducted by healthcare fintech vendor PayZen and the Healthcare Financial Management Association, found that 22% of respondents named patient balances as their top priority, roughly double the 11% rate reported a year prior. Patient balances were a “nearly universal” presence among the respondents’ concerns, also up from the 73% rate of a year prior. 
    • “Commercial revenue remained the respondents’ overall top priority, though the portion who indicated so dipped from last year’s 75% to 62%. Government program revenue also inched upward from 13% to 16%, naming it their top revenue concern.” 
  • and
    • “Maven, a virtual provider for women’s and family health, has launched its direct-to-consumer products featuring a virtual care clinic, a GLP-1 offering and a hormone therapy offering.
    • “They are available through cash-pay for now. The goal is to close gaps between prescriptions and follow-ups that GLP-1s and hormone therapies require. 
    • “In terms of pricing, the GLP-1s start at $150 a month. For the hormone product, there is a $150 1-time fee, which includes two virtual visits, in addition to medication costs. Specialty care visits in the virtual clinic are currently pay-per-visit, though insurance coverage for those is the eventual goal.”
  • BioPharma Dive tells us,
    • “Privately held Mentari Therapeutics plans to hit the public markets through a reverse merger with InMed Pharmaceuticals, creating a combined company focused on antibody drugs that can prevent migraines.
    • “The deal, announced Tuesday, has already received approval from the boards of both parties and is expected to close in the back half of this year. Terms hold that InMed shareholders would own roughly 1.5% of the combined company, which is slated to have a pro forma equity value of about $421 million. Baked into that value is a concurrent private placement that will result in gross proceeds of approximately $290 million.”
  • MedTech Dive informs us,
    • “Medtronic said Wednesday it has agreed to buy SPR Therapeutics, a company making a device that uses peripheral nerve stimulation to treat chronic pain.
    • “Under the terms of the deal, Medtronic would pay $650 million in cash to buy all outstanding equity in SPR Therapeutics. The purchase would add to Medtronic’s neuromodulation business, allowing the company to provide more pain relief options earlier in people’s care.
    • “The deal is Medtronic’s third major acquisition announced so far this year. In March, Medtronic agreed to buy neurovascular technology company Scientia Vascular for $550 million, and in February, the company announced plans to buy CathWorks, which makes tools to help detect coronary artery disease, for up to $585 million. Medtronic closed the CathWorks acquisition in April.”
  • Per Healthcare Dive,
    • Aetna’s chief digital and technology officer on how the insurer is using AI for patient engagement
    • Nathan Frank discusses how the insurer is using AI to engage members, how the company thinks about risks, and the importance of monitoring the tools and soliciting feedback.
  • Per Fierce BioTech,
    • “The big new thing in medtech for 2026 is AI-powered apps and chatbots designed to help patients navigate their laboratory test results. Now, testing giant Labcorp is getting in on the act. 
    • “The company is launching “MyLabcorp,” a mobile app that brings together lab results with AI-enabled features and clinical guideline-based content.
    • “The idea is that this can be viewed on a user’s phone via the app, giving users “additional context about their health and support more informed conversations with healthcare providers,” according to a May 20 statement.” 
  • Per Fierce Healthcare,
    • “Doximity plans to accelerate its spending on artificial intelligence this year as it aims to become a leading AI platform for doctors.
    • “The health tech company plans to up its R&D and compute spend along with more investments in brand marketing and its AI-enabled peer review capabilities, executives said during the company’s recent earnings call for its fiscal 2026 fourth quarter and full year results. The company’s 2027 fiscal year began April 1.
    • “The company plans to scale its clinical AI suite, including its ambient notetaking tool Scribe and clinical AI assistant and medical search engine Ask (formerly DoxGPT).” 

Tuesday report

A few years ago, the FEHBlog stopped including pictures because they disrupted the blog’s flow. It occurred to the FEHBlog that it could not hurt the flow to add a slogan which the FEHBlog appropriately am borrowing from the OPM Director Scott Kupor:

“Simplicity is a virtue.”

The FEHBlog chose this slogan to remind us that we should aim to simplify the healthcare system in our country, including the beloved FEHB and PSHB programs.

From Washington, DC,

  • Roll Call reports,
    • “The Homeland Security Department would get a new influx of funding to investigate child exploitation cases, including to identify victims of sexual abuse material online, under the GOP budget reconciliation bill. 
    • “The $108.5 million added in a substitute amendment Tuesday would support hiring additional investigators and forensic analysts within the department. The roughly $72 billion immigration enforcement package advanced out of the Senate Homeland Security and Governmental Affairs Committee on an 8-5 vote.
    • “Sen. Josh Hawley, R-Mo., pushed to include the funds in reconciliation, which he said would allow DHS to add 200 new positions to “rescue children who have been captured by sex trafficking, including a new program for local, state and federal law enforcement to coordinate their efforts.”
  • The Hill relates,
    • “The Department of Health and Human Services (HHS) on Monday withdrew its amended charter for a highly influential vaccine advisory committee that would have loosened eligibility requirements, citing administrative errors.
    • “In a notice set to be officially published in the Federal Register, HHS formally withdrew its proposed amendment to the charter for the Advisory Committee on Immunization Practices (ACIP) for the Centers for Disease Control and Prevention.”
  • Here’s a link to the White House’s fact sheet on yesterday’s expansion of TrumpRx to include 600 generic drugs.
  • Fierce Healthcare tells us,
    • “A new analysis from the Office of Inspector General found a similar net cost for drugs through vertically-integrated Part D plans compared to other plans.
    • “Vertically-integrated firms accounted for 35% of contracts Part D in 2023, according to OIG’s report. Eleven of the 300 organizations offering Part D coverage that year were considered vertically integrated, meaning they also owned a pharmacy benefit manager.
    • “While net drug costs were on par between the two types of organizations, the study found that vertically integrated firms came to those prices through different means than other organizations. In most cases, vertically integrated Part D plans paid pharmacies more initially but then clawed back more through fees and rebates to reach a net price.
    • “Other Part D plans, meanwhile, generally paid less upfront but also got less back from pharmacies later on.”
  • Per an HHS news release,
    • “The U.S. Department of Health and Human Services (HHS) today announced a $7.5 million investment to expand Americans’ access to high-quality protein, strengthen nutrition security, and reduce food waste nationwide. Through a new agreement with HATCH for Hunger, HHS will support a national initiative to redirect surplus protein to families in need, improve health outcomes, and help reduce the burden of chronic disease. This effort aligns with the Dietary Guidelines for Americans (DGAs), which emphasize the importance of protein-rich foods like meats, eggs, and dairy as part of a healthy diet.
    • “The U.S. Department of Agriculture (USDA) also announced its intent to fund a competitive grant program to strengthen cold chain infrastructure for emergency food assistance operations, including faith-based partners who serve communities in need. USDA will provide up to $7.5 million to help eligible nonprofit organizations safely distribute nutrient-dense proteins such as meat, eggs, seafood, and dairy to Americans in need. Additional information will be forthcoming from the Department.”
  • The American Hospital Association News informs us,
    • “The Centers for Medicare & Medicaid Services has released its fiscal year 2025 Program for Evaluating Payment Patterns Electronic Reports, or PEPPERs, for critical access hospitals. The reports help hospitals review their billing data to ensure accurate claims. They can be used to identify billing patterns that may need improvement, locate areas that may need audits or additional monitoring, find diagnosis-related groups that may be under- or over-coded, and track areas where patient stays are becoming longer. The reports can be accessed by authorized officials, access managers and users with the staff end user business function through CMS’ PEPPER Portal. CMS also has a guide and FAQ available for users on accessing the PEPPER. Additionally, CMS said it will host a webinar this summer for CAHs and short-term acute care hospitals.”
  • Modern Healthcare adds,
    • “The Health and Human Services Department Office of Inspector General is auditing every Medicaid Fraud Control Unit as it questions their efficacy.
    • “Medicaid fraud units recovered about $2 billion in fiscal 2025, but data show state to state variation in the level of convictions and recoupments.
    • “Providers should watch for tougher state enforcement as HHS scrutinizes state Medicaid fraud units.”

From the Food and Drug Administration front,

  • Healio reports,
    • “The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics.” * * *
    • “Coya 302 combines a low dose of IL-2 with CTLA-4 immunoglobulin in a subcutaneous form.
    • “The therapy enhances regulatory T-cell function while suppressing pro-inflammatory monocytes and macrophages.”
  • and
    • “The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis.
    • “Golimumab-sldi (Immgolis, Accord BioPharma) has been approved as a biosimilar to golimumab (Simponi, Johnson & Johnson) for adults with moderately to severely active ulcerative colitis. It is administered via subcutaneous injection in a single-dose prefilled syringe.”
  • and
    • “The FDA has proposed to withdraw its approval of avacopan for ANCA-associated vasculitis, alleging that employees of the original manufacturer, ChemoCentryx, manipulated data in the sole trial used to assess the drug’s efficacy. 
    • “In a letter to Amgen, which acquired avacopan (Tavneos) in its 2022 purchase of ChemoCentryx, Tracy Beth Høeg, MD, PhD, acting director of the FDA Center for Drug Evaluation and Research (CDER), also asserted that the original new drug application filed by ChemoCentryx contained false statements regarding the trial, known as the ADVOCATE study. The allegations follow post-marketing data released by the FDA in March identifying 76 cases of drug-induced liver injury with possible or probable causal links to avacopan, including seven cases of vanishing bile duct syndrome (VBDS). Of the 76 cases, eight were fatal.”

From the judicial front,

  • Bloomberg Law reports,
    • “At least two lawsuits alleging doctors are abusing arbitration for surprise medical bills are headed to the appeals circuit, escalating yet another issue under the No Surprises Act and creating more pressure on Congress and the Trump administration to revisit the system.” * * *
    • “Last month, Anthem Blue Cross Life and Health Insurance Co. appealed a US District Court’s ruling in California that rejected its ability to sue billing vendor HaloMD and doctor group Sound Physicians over ineligible claims, even though Anthem alerted the arbitrator to the issue. A federal court in Florida in April also ruledagainst Aetna because it didn’t alert the arbitrator that claims submitted by Radiology Partners were ineligible.
    • “The cases are now at the US Court of Appeals for the Ninth and Eleventh circuits, respectively.”
  • STAT News adds,
    • “A new dashboard produced by Turquoise Health, a company that specializes in price transparency data, illustrates just how lucrative the process has become for clinicians. The tool, which is free to use, compares the median in-network rates that health insurers and providers negotiate to the amounts out-of-network providers are being awarded for the same services under federal arbitration. The former comes from federal Transparency in Coverage files, and the latter from the Centers for Medicare and Medicaid Services. 
    • “It also shows the qualifying payment amounts (QPAs) for those services, which is calculated by the insurers and is supposed to represent the median in-network amount for the same service in that area. 
    • “The numbers are striking. Providers took home $9.8 billion in total awards across 5.3 million independent dispute resolution (IDR) decisions between 2023 and the first half of 2025. About 12% of that amount, or $1.2 billion, was fees paid to the arbiters. IDR awards were about nine times the QPA for the same service in the same area, although, as with the lumbar laminectomy, some ran much, much higher. 
    • “This just seems like an area where the costs are rampant and way over where they should be — certainly higher than CMS intended when they set all this stuff up,” said Leland Robbins, Turquoise Health’s senior director of data products.”
  • Per a Justice Department news release,
    • “A jury in the Central District of California convicted a California doctor yesterday in a $45 million scheme to defraud Medicare by submitting claims for Botox injections that were never provided and medically unnecessary, and for obstructing the investigation by manipulating and altering medical records in an attempt to mislead criminal investigators. The investigation was initiated as a result of a referral from the Health Care Fraud Section’s Data Analytics Team, after its analysis showed that the defendant was paid more by Medicare for Botox injections than any other doctor in the United States.
    • “Violetta Mailyan falsely diagnosed patients, fraudulently billed for Botox injections while she was actually on lavish vacations, and tried to trick federal agents with fake records,” said Assistant Attorney General Colin M. McDonald of the Justice Department’s National Fraud Enforcement Division. “The Fraud Division’s data-driven approach will shine a light on fraud schemes across the country, ensuring that no doctor can engage in these types of brazen schemes to rob Medicare.”

From the public health and medical / Rx research front,

  • STAT News reports,
    • “The idea of drinking during pregnancy sounds like a generational punchline: Someone’s grandmother drank beer to fatten her fetus, another had a nightly martini to get a healthy amount of sleep — presumably unthinkable behavior in today’s America. 
    • “Yet after precipitous declines in the last 50 years, rates of alcohol use in pregnancy in the U.S. started climbing upward a decade ago. More than 1 in 8 pregnant adults reported drinking in the past month, according to STAT’s analysis of 2024 government data, making alcohol use a more common national phenomenon than gestational diabetes. Of those who drank, a quarter reported having four or more drinks in one sitting — binge drinking — in the prior month. 
    • “While rates of alcohol use in pregnancy are lower in the U.S. than those of several peer nations, the effects are all around Americans. Alcohol is the key driver of what are, by some estimates, the nation’s top neurodevelopmental conditions: fetal alcohol spectrum disorders, or FASDs.
    • “The exact prevalence of FASDs is difficult to measure, but the most recent federally funded community studies have found as many as 1 in 20 school-aged children may have a disorder caused by prenatal alcohol exposure. By comparison, about 1 in 31 American children has autism, per recent estimates from the Centers for Disease Control and Prevention.
    • “Not all fetuses exposed to alcohol have birth defects or go on to develop intellectual disabilities, researchers say. But every person born with an FASD was harmed by alcohol specifically. They worry this point is being glossed over as Americans question the conventional medical advice of avoiding all alcohol while pregnant.”
  • The latest post of the National Institutes of Health’s Research Matters covers the following topics:
    • Team-based care improves blood pressure control
      • “Researchers found that a multifaceted intervention was better than a standard approach at reducing high blood pressure among low-income patients.
      • “Similar multifaceted, team-based strategies could be implemented widely to benefit underserved populations.”
    • Effects of early exposure to toxic metals
      • “Scientists found that toxic metal exposures during specific time windows increased the risk of brain and mental health symptoms a decade later.
      • “These results support the need for preventing excessive early life metal exposures and associated harms.”
    • Scientists spur growth of implanted liver tissue
      • “Researchers developed a way to control the growth of lab-grown liver tissue after it was implanted into mice.
      • “The technique could one day lead to alternative treatments for people who need organ transplants.”
  • Health Day relates,
    • “Long-term exposure to smog might increase the risk of Lewy body dementia, the brain disease that CNN founder Ted Turner battled for several years before his recent death, a new study says.
    • “Even small increases in particle pollution and nitrogen dioxide are linked to increased risk of Lewy body dementia (LBD) and Parkinson’s disease-related dementia, researchers reported May 14 in JAMA Network Open.
    • “People’s risk of LBD nearly quadrupled for every incremental increase in exposure to particle pollution, researchers found.
    • “Similarly, risk for Parkinson’s-related dementia more than doubled for every such increase in particle pollution exposure, the study found.
    • “While this research does not establish causation, it does show a clear association between air pollution exposure and increased risk of these dementias,” said researcher Dr. Gregory Pontone, chief of the Aging, Behavioral and Cognitive Neurology Division at the University of Florida in Gainesville.”
  • and
    • “New-onset atrial fibrillation (AF) may accelerate kidney function decline, according to a study published online May 14 in JAMA Network Open.
    • “Yuichiro Mori, M.D., from Kyoto University in Japan, and colleagues conducted a retrospective cohort study to examine the association of new-onset AF with subsequent kidney function decline in working-age adults. Participants included screening attendees aged 35 to 59 years in sinus rhythm without previous AF, cardiovascular comorbidities, or end-stage kidney disease. A total of 23,510 adults who developed new-onset AF during the annual screening interval were matched in a 1:5 ratio to 117,550 individuals who did not develop new-onset AF.”
    • * * * “This finding suggests the importance of cardiovascular-kidney-metabolic perspectives in AF management,” the authors write. “Further investigation is needed on the cumulative impact of AF on chronic kidney disease progression and on the effectiveness of AF treatments for improving kidney outcomes.”
  • The Washington Post informs us,
    • “Modern psychiatry has long struggled with one brutal fact: the people most at risk of suicide often cannot wait weeks for therapy or antidepressants to work. Now, a new study suggests researchers may have found the first drug regimen capable of rapid and sustaining relief from suicidal thoughts across a broad group of patients.
    • “Suicide remains one of the nation’s most urgent public health crises, with roughly 13 million Americans seriously considering it each year and about 50,000 dying by suicide annually.
    • “A study to be presented Tuesday at the American Psychiatric Association’s annual meeting found that a surprising combination of drugs — a single ketamine infusion followed by low-dose buprenorphine — significantly sustained reductions in suicidal ideation in adults with major depressive disorder.
    • “This is really a breakthrough study that provides hope and immediate clinical applications,” said Ned Kalin, editor-in-chief of the journal that will publish the paper and chair of the Department of Psychiatry at the University of Wisconsin School of Medicine and Public Health.
    • “But outside experts who were not involved in the study urged caution.
    • “Bertha Madras, a professor of psychobiology at Harvard Medical School, said that while the findings are intriguing, doctors should be careful not to move too quickly.”
  • Genetic Engineering and Biotechnology News points out,
    • “A University of Bath-led research effort received £500,000 to develop an organ-on-chip device that replicates connections between the brain, gut, and pancreas. The GlucoBrain project is designed to allow researchers to track how signals move between the organs and uncover why diabetes may lead to changes in memory and cognition.
    • “Collaborators include investigators from the University of Oxford and Johns Hopkins. Their findings could pave the way for new treatments to improve the lives of millions of people affected by diabetes, dementia, or both, notes the team.
    • ‘Diabetes and Alzheimer’s disease are two of the world’s most pressing health problems, especially in aging societies. While diabetes is widely known to affect the heart, kidneys, and eyes, growing evidence suggests it is also linked with problems in memory, learning, and brain function. However, the biological mechanisms behind this link remain poorly understood.
    • “Our gut, pancreas, and brain are constantly communicating via a network of signals, helping us regulate hunger and blood sugar,”  says Despina Moschou, PhD, project lead. “But we still don’t fully understand how these signals interact at a cellular level and why glucose levels are linked to cognitive decline. “By creating a connected system on a chip, we can study in real time how signals travel between organs, how diabetes may impair brain function, and how new drugs could help.”
  • MedPage notes,
    • “Men treated with GLP-1 receptor agonists had significant increases in testosterone levels, according to findings from a retrospective analysis.
    • “Among men who received semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), median total testosterone increased from 320 to 419 ng/dL and median free testosterone increased from 9.0 to 10.4 ng/dL (P<0.001 for both), reported Andrés Heriberto Guillén-Lozoya, MD, of the Mayo Clinic in Rochester, Minnesota, at the American Urological Associationopens in a new tab or window annual meeting.
    • “After adjusting for age and body mass index (BMI), total testosterone increased by a median of 97.6 ng/dL, while free testosterone increased by 1.3 ng/dL (P<0.001 for both).
    • “Meanwhile, median BMI decreased from 33.6 to 30.4 (P<0.001).”
  • Per BioPharma Dive,
    • “A drug prospect from Relay Therapeutics has shown signs in a mid-stage clinical trial that it may be able to treat a cluster of conditions associated with the development of abnormal blood vessels.
    • “In 20 people with these “vascular anomalies,” a 12-week regimen of Relay’s therapy, zovegalisib, was associated with a 60% response rate across all doses tested, the company said Tuesday. Nearly all patients experienced an improvement in symptoms, and responses were observed in people with different disease subtypes and “PIK3CA” mutations driving their condition.
    • “Investigators did have to dial back dosing in 23% of people getting one of the doses Relay will take into further testing. But the company also said no patients discontinued treatment, most common adverse events were “low-grade, manageable, and reversible” and the drug appeared safe enough to envision the kind of “chronic use” that’d be necessary for these conditions. Company shares climbed by about 10% in early Tuesday trading.”
  • Per Fierce Pharma,
    • “Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis (PsA), the Belgian drugmaker has unveiled the detailed results.
    • ‘In the phase 3b study that included 553 patients, 49% of those on Bimzelx achieved reduced disease activity versus 38% of those on Skyrizi at week 16. The result was deemed to be statistically significant, UCB said.
    • “The disease activity primary endpoint was measured by ACR50, which is a composite efficacy measurement, specified by the American College of Rheumatology, which indicates 50% or greater improvement from baseline in tender or swollen joint counts in addition to 50% improvement in three of five other disease markers.”
  • Per MedTech Dive,
    • “Boston Scientific said Tuesday a pivotal study of its coronary intravascular lithotripsy catheter to treat severely calcified coronary artery disease met its primary safety and effectiveness endpoints.
    • “The data, presented at the EuroPCR 2026 conference in Paris, showed a 93.3% rate of freedom from major adverse cardiac events at 30 days, exceeding the primary safety goal of 86.2%. The device demonstrated 93.7% procedural success, defined as stent delivery with residual stenosis of less than 50% and no major adverse events during the hospital stay, exceeding the 85.8% goal.
    • “Boston Scientific said the study results will support its regulatory submission for the Seismiq 4CE catheter to address severe calcium during the lesion preparation phase of percutaneous coronary interventions to open blocked arteries.”

From the U.S. healthcare business and artificial intelligence front,

  • Corporate Insight discusses “How Leading Health Plans Are Rethinking the Claims Experience.”
    • “For years, the claims experience has been one of the most friction-heavy touchpoints in healthcare. Members struggle to understand their Explanation of Benefits, navigate claim submission processes and track reimbursement status—often ending up on the phone with member services when the digital channel fails them. Corporate Insight’s April 2026 Health Plan Monitor Update noted two major plans addressing this from different angles: Aetna through contextual cost explanation at the point of confusion, and UnitedHealthcare through a structured, self-service submission overhaul.
    • “The two approaches are complementary. One tackles post-service, helping members understand a claim after it has been processed. The other addresses submission, reducing friction when members initiate a claim. Together, they reflect a maturing view of what claims look like in the digital experience.”
  • MedCity News calls attention to
    • “What Seasonal Pressures Continue to Teach Us About the Fragility of the US Surgical System
    • “When demand fluctuates, even slightly, the margin for error becomes clear – highlighting the urgent need for greater efficiency to meet rising procedural demand.”
  • Modern Healthcare adds,
    • “Health systems are improving the profitability of their operating rooms through efficiency upgrades.
    • “Trinity Health, WellSpan and UCI Health are among many health systems redesigning spaces and using data to maximize the OR’s potential.
    • “Declining reimbursement will require health systems to become more efficient, executives said.”
  • STAT News relates,
    • “Here’s one more sign of Eli Lilly’s dominance in the drug industry: It took both top spots in a prominent ranking of pharmaceutical innovators and investors.
    • “The index, produced by U.K.-based IDEA Pharma, ranks drug company laboratories on two different sets of criteria: innovation, which takes into account revenue from new products, new drug approvals, and major drug development events; and invention, which looks at the number of drugs a company has in development, its clinical trials, and its R&D investment, among other factors. IDEA is part of SAI MedPartners, a larger consultancy.”
    • “This is the first time that one company — in this case, Lilly — has ranked No. 1 in both categories.”
       
  • Beckers Health IT adds,
    • “Several startups with a footprint in healthcare [listed in the article] made CNBC’s annual Disruptor 50 rankings May 19, with one AI giant surpassing a rival in 2026.
    • “Anthropic passed OpenAI to rank No. 1 on this year’s list, with both companies having recently unveiled healthcare AI offerings. An advisory board weighs the criteria for the rankings, which are based on detailed quantitative and qualitative information submitted by nominated companies.”
  • Fierce Healthcare lets us know,
    • “Online health and wellness company Hims & Hers posted a $92 million loss in the first quarter as it shifts its business from selling compounded weight loss drugs to branded GLP-1 medications.
    • “During the same period a year ago, Hims & Hers posted a profit of $49.5 million.
    • “The company brought in revenue of $608 million in Q1, up 4% year-over-year. The company’s stock was down about 15% in mid-day trading on Tuesday following the unexpected Q1 loss. Revenue also missed Wall Street analysts’ expectations. Hims & Hers reported a loss of 40 cents per share in Q1 2026 compared to the Zacks Consensus Estimate of EPS of a profit of 4 cents. Revenue also missed the Zacks Consensus Estimate by 1.9%.”
  • and
    • “Nourish, a virtual nutrition-focused metabolic provider, has raised $100 million in a series C round. 
    • “The round was led by Menlo Ventures, with participation from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator and more. The capital will be used to grow Nourish’s provider workforce, accelerate its investment in AI and deepen partnerships with payers and health systems.
    • “The company is pivoting from being a dietitian-only nutrition platform to a more comprehensive metabolic health clinic by hiring physicians. Nourish patients are typically paired with a registered dietitian, but now lab testing, GLP-1 prescriptions and other virtual care are also becoming available. There is currently a waitlist to see Nourish physicians, though the goal is to rapidly expand by the end of this year to meet the “overwhelming demand,” per executives.”
  • and
    • “Healthcare AI company Commure has banked $70 million in fresh funding, reaching a $7 billion valuation.
    • “General Catalyst led the funding round, which also included participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis, according to an announcement. Commure said that it will use the funds to scale its platform and continue building out its technology.
    • “The company offers AI tools and agents that embed in the workflow of health systems and providers. Its tech is largely focused on simplifying administrative work, which Commure said consumes about $1 trillion each year across the country.
    • “Its revenue cycle management tool and advanced clinical workflow tool are deployed across more than 500 organizations that include more than 3,000 sites of care, Commure said in the announcement. Among those are more than 130 of the largest health systems in the country, such as Tenet Healthcare and HCA Healthcare.”
  • MedCity News points out,
    • “John Ayers believes most healthcare AI hype has not yet translated into meaningful patient impact — though he thinks that may soon change. This belief drove Ayers and a team of researchers to create ChatCPR, an AI agent launched this week that coaches users through CPR in real time.
    • ‘Ayers, head of AI at the University of California San Diego’s Altman Clinical and Translational Research Institute, is the lead author of a widely discussed 2023 JAMAstudy that found AI chatbots’ responses to patient messages are often more accurate and empathic than those written by human doctors.” * * *
    • “So, the researchers built ChatCPR to handle more advanced, guideline-critical details. A study published Monday in JAMA not only introduced the tool but also showed that it outperformed 911 dispatchers in guiding bystanders through CPR when tested against recordings from real 911 calls.
    • “The research team rolled out ChatCPR this week as an open-source public resource rather than a commercial product. They are making the training materials, guidelines, prompts and architecture publicly available so that the right companies and emergency-response organizations can build on it, improve it and deploy it broadly, Ayers said.
    • “In his eyes, the key challenge in healthcare AI is implementation — not necessarily having the most advanced model. This is why the team intentionally built ChatCPR on a relatively small, lower-performing language model and still achieved strong results through careful design and domain-specific training. 
    • “Ayers said this means the tool could eventually run directly on smartphones without requiring internet connectivity.”
  • The Wall Street Journal adds,
    • “Yes, AI Can Make Mistakes. AI Can Find Them, Too.
    • “Since chatbots hallucinate their own facts, it’s useful (and easy) to have a second, nitpicking AI that can audit the results for errors.”